MedMen Enterprises (MMNFQ) 10-Q 12 May 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Mar. 27, 2021	May 07, 2021
Cover [Abstract]
Entity Registrant Name	MedMen Enterprises, Inc.
Entity Central Index Key	0001776932
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 27, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		664,200,870
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	A1
Entity File Number	000-56199

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Balance Sheets - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Current Assets:
Cash and Cash Equivalents	$ 21,313,672	$ 9,418,501
Restricted Cash	730	1,029
Accounts Receivable and Prepaid Expenses	6,658,615	5,532,044
Inventory	17,047,620	18,976,978
Current Assets Held for Sale	64,216,871	37,900,006
Other Current Assets	8,177,203	9,105,457
Due from Related Party		3,109,717
Total Current Assets	117,414,711	84,043,732
Operating Lease Right-of-Use Assets	74,873,584	95,262,366
Property and Equipment, Net	134,176,989	163,623,095
Intangible Assets, Net	115,334,085	136,405,145
Goodwill	32,900,458	32,900,458
Non-Current Assets Held for Sale		46,228,551
Other Assets	12,630,961	15,800,257
TOTAL ASSETS	487,330,788	574,263,604
Current Liabilities:
Accounts Payable and Accrued Liabilities	58,087,253	75,425,161
Income Taxes Payable	51,795,935	38,770,314
Other Current Liabilities	20,722,125	20,278,381
Current Portion of Operating Lease Liabilities	8,704,279	8,318,506
Current Portion of Finance Lease Liabilities	204,770	1,644,044
Current Portion of Notes Payable	97,169,640	16,188,668
Current Liabilities Held for Sale	44,523,220	24,033,005
Due to Related Party	1,476,921	4,556,814
Total Current Liabilities	282,684,143	189,214,893
Operating Lease Liabilities, Net of Current Portion	96,779,586	110,928,400
Finance Lease Liabilities, Net of Current Portion	28,440,822	58,569,498
Other Non-Current Liabilities	3,790,561	4,215,533
Non-Current Liabilities Held for Sale		28,502,256
Deferred Tax Liabilities	48,105,032	40,543,074
Senior Secured Convertible Credit Facility	157,065,410	166,368,463
Notes Payable, Net of Current Portion	92,845,744	152,809,937
TOTAL LIABILITIES	709,711,298	751,152,054
MEZZANINE EQUITY:
Super Voting Shares (no par value, unlimited shares authorized, nil and 815,295 shares issued and outstanding as of March 27, 2021 and June 27, 2020, respectively)		82,500
SHAREHOLDERS' EQUITY:
Preferred Shares (no par value, unlimited shares authorized and no shares issued and outstanding)
Subordinate Voting Shares (no par value, unlimited shares authorized, 625,769,627 and 403,907,218 shares issued and outstanding as of March 27, 2021 and June 27, 2020, respectively)
Additional Paid-In Capital	892,713,747	791,172,613
Accumulated Deficit	(679,595,695)	(631,365,866)
Total Equity Attributable to Shareholders of MedMen Enterprises Inc.	213,118,052	159,889,247
Non-Controlling Interest	(435,498,562)	(336,777,697)
TOTAL MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY	(222,380,510)	(176,888,450)
TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY	$ 487,330,788	$ 574,263,604

Unaudited Interim Condensed C_2

Unaudited Interim Condensed Consolidated Balance Sheets (Parenthetical) - shares	Mar. 27, 2021	Jun. 27, 2020
Super Voting Shares [Member]
Stockholders' deficit
Preferred stock, shares issued	0	815,295
Preferred stock, shares outstanding	0	815,295
Subordinate Voting Shares [Member]
Stockholders' deficit
Preferred stock, shares issued	625,769,627	403,907,218
Preferred stock, shares outstanding	625,769,627	403,907,218

Unaudited Interim Condensed C_3

Unaudited Interim Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Income Statement [Abstract]
Revenue	$ 32,028,679	$ 44,064,955	$ 96,390,475	$ 123,391,681
Cost of Goods Sold	18,707,174	30,429,063	50,666,827	78,575,746
Gross Profit	13,321,505	13,635,892	45,723,648	44,815,935
Expenses:
General and Administrative	28,939,691	42,957,935	89,686,896	150,774,000
Sales and Marketing	127,570	1,047,996	524,209	10,440,773
Depreciation and Amortization	7,950,490	7,476,622	24,837,550	22,351,909
Realized and Unrealized Loss on Changes in Fair Value of Contingent Consideration		962,791	390,727	8,462,116
Impairment Expense	1,573,563		2,363,272
Other Operating Expense (Income)	1,558,530	1,848,209	(24,818,043)	6,783,169
Total Expenses	40,149,844	54,293,553	92,984,611	198,811,967
Loss from Operations	(26,828,339)	(40,657,661)	(47,260,963)	(153,996,032)
Other Expense (Income):
Interest Expense	10,114,050	7,136,316	26,574,962	21,313,190
Interest Income	(41,915)	(126,089)	(582,980)	(760,809)
Amortization of Debt Discount and Loan Origination Fees	8,166,700	1,511,085	14,634,267	3,289,863
Change in Fair Value of Derivatives	(1,938,995)	(11,725)	(2,066,495)	(8,041,429)
Realized and Unrealized Gain on Investments		(86,124)		(16,600,604)
Loss on Extinguishment of Debt	6,420,526	11,570,696	17,493,887	43,800,931
Total Other Expense	22,720,366	19,994,159	56,053,641	43,001,142
Loss from Continuing Operations Before Provision for Income Taxes	(49,548,705)	(60,651,820)	(103,314,604)	(196,997,174)
Provision for Income Tax Benefit (Expense)	32,207,910	13,836,022	(2,101,121)	47,088,266
Net Loss from Continuing Operations	(17,340,795)	(46,815,798)	(105,415,725)	(149,908,908)
Net Income (Loss) from Discontinued Operations, Net of Taxes	7,609,983	(5,843,713)	(6,023,429)	(58,797,102)
Net Loss	(9,730,812)	(52,659,511)	(111,439,154)	(208,706,010)
Net Loss Attributable to Non-Controlling Interest	3,987,882	(27,687,295)	(26,105,114)	(118,260,518)
Net Loss Attributable to Shareholders of MedMen Enterprises Inc.	$ (13,718,694)	$ (24,972,216)	$ (85,334,040)	$ (90,445,492)
Income (Loss) Per Share - Basic and Diluted:
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.	$ (0.04)	$ (0.06)	$ (0.18)	$ (0.48)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.	$ 0.01	$ (0.02)	$ (0.01)	$ (0.89)
Weighted-Average Shares Outstanding - Basic and Diluted	541,029,620	315,384,911	482,213,951	65,930,969

Unaudited Interim Condensed C_4

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Super Voting	Subordinate Voting	Additional Paid-In Capital	Accumulated Deficit	Total equity attributable to Shareholders of Medmen	Noncontrolling Interest	Total
Balance, shares at Jun. 28, 2019	1,630,590	173,010,922
Balance, amount at Jun. 28, 2019	$ 164,999		$ 613,356,006	$ (370,382,824)	$ 243,138,181	$ (31,867,405)	$ 211,270,776
Net Loss				(90,445,492)	(90,445,492)	(118,260,518)	(208,706,010)
At-the-Market Equity Financing Program, Net, shares		9,789,300
At-the-Market Equity Financing Program, Net, amount			12,399,249		12,399,249		12,399,249
Shares Issued for Cash, shares		61,596,792
Shares Issued for Cash, amount			50,193,938		50,193,938		50,193,938
Shares Issued to Settle Debt and Accrued Interest, shares		6,801,790
Shares Issued to Settle Debt and Accrued Interest, amount			5,255,172		5,255,172		5,255,172
Shares Issued to Settle Accounts Payable and Liabilities, shares		15,847,581
Shares Issued to Settle Accounts Payable and Liabilities, amount			5,684,851		5,684,851		5,684,851
Shares Issued to Settle Contingent Consideration, shares		13,737,444
Shares Issued to Settle Contingent Consideration, amount			11,559,875		11,559,875		11,559,875
Asset Acquisitions, shares		7,373,034
Asset Acquisitions, amount			4,904,381		4,904,381		4,904,381
Equity Component of Debt - New and Amended			23,093,250		23,093,250		23,093,250
Redemption of MedMen Corp Redeemable Shares, shares		27,090,259
Redemption of MedMen Corp Redeemable Shares, amount			31,690,004	(27,862,104)	3,827,900	(3,827,900)
Shares Issued for Vested Restricted Stock Units, shares		329,548
Shares Issued for Vested Restricted Stock Units, amount
Shares Issued for Other Assets, shares		13,479,589
Shares Issued for Other Assets, amount			7,862,916		7,862,916		7,862,916
Shares Issued for Acquisition Costs, shares		269,817
Shares Issued for Acquisition Costs, amount			429,314		429,314		429,314
Shares Issued for Business Acquisition, shares		5,112,263
Shares Issued for Business Acquisition, amount			9,833,000		9,833,000		9,833,000
Stock Grants for Compensation, shares		2,531,763
Stock Grants for Compensation, amount			3,005,795		3,005,795	35,217	3,041,012
Share-Based Compensation			6,312,418		6,312,418		6,312,418
Deferred Tax Impact On Conversion Feature				(260)	(260)		(260)
Cancellation of Super Voting Shares, shares	(815,295)
Cancellation of Super Voting Shares, amount	$ (82,500)		82,500
Non-Controlling Interest Equity Transactions: Distributions						(310,633)	(310,633)
Non-Controlling Interest Equity Transactions: Equity Component of Debt - New and Amended						5,331,969	5,331,969
Non-Controlling Interest Equity Transactions: Share-Based Compensation						1,492,073	1,492,073
Balance, shares at Mar. 28, 2020	815,295	336,970,102
Balance, amount at Mar. 28, 2020	$ 82,500		785,662,669	(488,690,680)	297,054,488	(147,407,197)	149,647,291
Balance, shares at Jun. 27, 2020	815,295	403,907,218
Balance, amount at Jun. 27, 2020	$ 82,500		791,172,613	(631,365,866)	159,889,247	(336,777,697)	(176,888,450)
Net Loss				(85,334,040)	(85,334,040)	(26,105,114)	(111,439,154)
Shares Issued for Cash, shares		57,800,000
Shares Issued for Cash, amount			18,885,912		18,885,912		18,885,912
Fair Value of Warrants - Private Placement Cost, amount			(7,228,135)		(7,228,135)		(7,228,135)
Shares Issued to Settle Accounts Payable and Liabilities, shares		14,911,047
Shares Issued to Settle Accounts Payable and Liabilities, amount			2,755,853		2,755,853		2,755,853
Equity Component of Debt - New and Amended			53,854,490		53,854,490		53,854,490
Redemption of MedMen Corp Redeemable Shares, shares		133,969,228
Redemption of MedMen Corp Redeemable Shares, amount			31,992,438	43,468,394	75,460,832	(75,460,832)
Shares Issued for Vested Restricted Stock Units, shares		7,173,256
Shares Issued for Vested Restricted Stock Units, amount			437,386		437,386		437,386
Warrants Issued Pursuant to Debt Agreements			7,834,885		7,834,885		7,834,885
Stock Grants for Compensation, shares		3,703,730
Stock Grants for Compensation, amount			693,659		693,659		693,659
Deemed Dividend - Down Round Feature of Warrants			6,364,183	(6,364,183)
Share-Based Compensation			3,033,421		3,033,421		3,033,421
Deferred Tax Impact On Conversion Feature			(19,175,962)		(19,175,962)	(1,210,052)	(20,386,014)
Cancellation of Super Voting Shares, shares	(815,295)
Cancellation of Super Voting Shares, amount	$ (82,500)		82,500
Debt Amendment Fees Settled in Equity, shares		4,305,148
Debt Amendment Fees Settled in Equity, amount			2,010,504		2,010,504		2,010,504
Non-Controlling Interest Equity Transactions: Equity Component on Debt and Debt Modification						4,055,133	4,055,133
Balance, shares at Mar. 27, 2021		625,769,627
Balance, amount at Mar. 27, 2021			$ 892,713,747	$ (679,595,695)	$ 213,118,052	$ (435,498,562)	$ (222,380,510)

Unaudited Interim Condensed C_5

Unaudited Interim Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss from Continuing Operations	$ (105,415,725)	$ (149,908,908)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Deferred Tax (Recovery) Expense	(10,862,478)	(62,961,468)
Depreciation and Amortization	25,221,168	24,438,013
Non-Cash Operating Lease Costs	20,935,916	19,076,003
Accretion of Debt Discount and Loan Origination Fees	14,634,266	3,289,863
Loss on Disposal of Asset	669,601
Gain on Lease Modifications	(17,748,458)
Accretion of Deferred Gain on Sale of Property	(424,972)	(424,970)
Impairment of Assets	2,363,272
Realized and Unrealized Gain on Investments, Assets Held for Sale and Other Assets	(10,709,999)	(16,600,604)
Change in Fair Value of Contingent Consideration	390,727	8,462,116
Change in Fair Value of Derivative Liabilities	(2,066,495)	(8,041,429)
Loss on Extinguishment of Debt and Settlement of Accounts Payables and Accrued Liabilities	17,493,994	43,800,931
Share-Based Compensation	4,164,466	10,845,503
Interest Capitalized on Finance Lease Liabilities	707,965
Shares Issued for Acquisition Costs		429,314
Changes in Operating Assets and Liabilities:
Accounts Receivable and Income Taxes Receivable	(1,126,571)	(1,385,228)
Prepaid Rent - Related Party		2,712,237
Prepaid Expenses	(171)	8,141,338
Inventory	1,929,358	5,002,584
Other Current Assets	1,926,650	6,095,806
Due from Related Party	3,109,717	782,866
Other Assets	2,769,296	(13,346,695)
Accounts Payable and Accrued Liabilities	(2,090,168)	29,602,480
Income Taxes Payable	12,857,702	14,375,083
Other Current Liabilities	28,426,057	9,102,790
Interest Payments on Finance Leases	(4,061,842)	(4,617,716)
Cash Payments - Operating Lease Liabilities	(15,611,252)	(16,892,734)
Due to Related Party	(3,079,893)	(717,847)
Other Non-Current Liabilities	0	787,492
NET CASH USED IN CONTINUED OPERATING ACTIVITIES	(35,597,869)	(87,953,180)
Net Cash Used in Discontinued Operating Activities	(8,068,255)	(4,746,067)
NET CASH USED IN OPERATING ACTIVITIES	(43,666,124)	(92,699,247)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of Property and Equipment	(3,451,958)	(44,829,009)
Additions to Intangible Assets	(622,329)	(2,686,488)
Proceeds from the Sale of Investments	0	12,500,000
Proceeds from Sale of Assets Held for Sale and Other Assets	19,002,185	21,947,797
Proceeds from Sale of Property	0	9,300,000
Acquisition of Businesses, Net of Cash Acquired	0	(1,000,000)
Restricted Cash	299	39,324
NET CASH PROVIDED BY (USED IN) CONTINUED INVESTING ACTIVITIES	14,928,198	(4,728,376)
Net Cash Used in Discontinued Investing Activities	0	(8,540,311)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	14,928,198	(13,268,687)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of Subordinate Voting Shares for Cash	18,885,912	62,593,187
Payment of Loan Amendment Fee	0	(500,000)
Proceeds from Issuance of Senior Secured Convertible Credit Facility	14,577,000	47,500,000
Proceeds from Issuance of Notes Payable	15,830,279	13,850,000
Principal Repayments of Senior Secured Convertible Credit Facility	(8,000,000)	0
Principal Repayments of Notes Payable	(660,094)	(14,922,455)
Principal Repayments of Finance Lease Liability	0	(807,432)
Debt and Equity Issuance Costs	0	(1,859,784)
Distributions - Non-Controlling Interest	0	(310,633)
NET CASH PROVIDED BY FINANCING ACTIVITIES	40,633,097	105,542,883
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	11,895,171	(425,051)
Cash and Cash Equivalents, Beginning of Period	9,418,501	32,172,302
CASH AND CASH EQUIVALENTS, END OF PERIOD	21,313,672	31,747,251
SUPPLEMENTAL DISCLOSURE FOR CASH FLOW INFORMATION
Cash Paid for Interest	7,398,733	19,400,295
Non-Cash Investing and Financing Activities:
Net Assets Transferred to Held for Sale	6,614,987	11,823,655
Adoption of ASC 842 - Leases	0	144,602,158
Relief of Accounts Payable for Return of Property and Equipment	1,748,396	0
Receivable Recorded on Asset Held for Sale	6,172,096	0
Fair Value of Warrants - Private Placement Cost	7,228,135	0
Lease Termination and Amendments	37,250,808	0
Recognition of Right-of-Use Assets for Finance Leases	0	45,614,041
Paid-in-Kind Interest Capitalized to Debt	32,332,500	0
Settlement of Contingent Consideration with Shares	0	11,559,875
Increase in Fair Value of Contingent Consideration Related to Asset Acquisition	0	9,374,487
Issuance of Subordinate Voting Shares for Intangible Assets and Other Assets	0	12,767,297
Redemption of MedMen Corp Redeemable Shares	75,460,832	3,827,900
Equity Component of Debt Modification - Non-Controlling Interest	0	5,331,969
Release of Investments for Liabilities	750,000	0
Shares Issued to Settle Debt and Accrued Interest	7,228,135	5,684,851
Shares Issued to Settle Accounts Payable and Liabilities	2,755,853	4,849,310
Equity Component of Debt - New and Amended	5,583,407	23,781,053
Accrued Interest Added to Senior Secured Convertible Debt	0	10,247,255
Deferred Tax Impact on Conversion Feature	$ 20,386,014	$ 260

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Mar. 27, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Note 1. NATURE OF OPERATIONS	1. NATURE OF OPERATIONS MedMen Enterprises Inc. (“MedMen Enterprises” or the “Company”), formerly known as Ladera Ventures Corp., was incorporated under the Business Corporations Act (British Columbia) on May 21, 1987. The Company’s Class B Subordinate Voting Shares are listed on the Canadian Securities Exchange under the symbol “MMEN”, on the OTCQX under the symbol “MMNFF”, on the Frankfurt Stock Exchange under the symbol “OJS.F”, on the Stuttgart Stock Exchange under the symbol “OJS.SG”, on the Munich Stock Exchange under the symbol “OJS.MU”, on the Berlin Stock Exchange under the symbol “OJS.BE” and on the Dusseldorf Stock Exchange under the symbol “OJS.DU”. The head office and principal address of the Company is 10115 Jefferson Boulevard, Culver City, California 90232. The Company’s registered and records office address is 885 West Georgia Street, Suite 2200, Vancouver, British Columbia Canada V6C 3E8. The Company operates through its principal wholly-owned subsidiaries, MM CAN USA, Inc., a California corporation (“MM CAN” or “MedMen Corp”), and MM Enterprises USA, LLC, a Delaware limited liability company (“MM Enterprises USA”). MM CAN was converted into a California corporation (from a Delaware corporation) on May 16, 2018 and is based in Culver City, California. The head office and principal address of MM CAN is 10115 Jefferson Boulevard, Culver City, California 90232. MM Enterprises USA was formed on January 9, 2018 and is based in Culver City, California. The head office and principal address of MM Enterprises USA is 10115 Jefferson Boulevard, Culver City, California 90232. MM Enterprises USA was formed as a joint venture whose contributors were MMMG, LLC (“MMMG”); MedMen Opportunity Fund, LP (“Fund I”); MedMen Opportunity Fund II, LP (“Fund II”), The MedMen of Nevada 2, LLC (“MMNV2”); DHSM Investors, LLC (“DHS Owner”); and Bloomfield Partners Utica, LLC (“Utica Owner”) (collectively, the “MedMen Group of Companies”). On January 24, 2018, pursuant to a Formation and Contribution Agreement (the “Agreement”), a roll-up transaction was consummated whereby the assets and liabilities of the MedMen Group of Companies were transferred into MM Enterprises USA. In return, the MedMen Group of Companies received 217,184,382 MM Enterprises USA Class B Units. The Agreement was entered into by and among MM Enterprises Manager, LLC, the sole manager of MM Enterprises USA; MMMG; Fund I; Fund II; MMNV2; DHS Owner; and Utica Owner.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Mar. 27, 2021
Accounting Policies [Abstract]
Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Preparation The accompanying unaudited interim Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). The unaudited interim Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of March 27, 2021 and June 27, 2020, the consolidated results of operations for the three and nine months ended March 27, 2021 and March 28, 2020, and the consolidated statements of cash flows for the nine months ended March 27, 2021 and March 28, 2020 have been included. The accompanying unaudited interim Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements, prepared in accordance with GAAP, have been condensed or omitted in accordance with SEC rules and regulations within the instruction to Form 10-Q and Article 10 of Regulation S-X. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in Item 13 of the registration statement on Form 10 for the fiscal year ended June 27, 2020. Going Concern As reflected in the unaudited interim Condensed Consolidated Financial Statements, the Company had an accumulated deficit and a negative net working capital (current liabilities greater than current assets) as of March 27, 2021, as well as a net loss and negative cash flow from operating activities for the reporting period then ended. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these unaudited interim Condensed Consolidated Financial Statements. Management believes that substantial doubt of our ability to meet our obligations for the next twelve months from the date these financial statements were first made available has been alleviated due to, but not limited to, (i) capital raised between May 2021 and May 2022, (ii) restructuring plans that have already been put in place to reduce corporate-level expenses, (iii) debt amendments that have been agreed to with lenders and landlords to defer cash interest and rent payments, (iv) rationalization of capital expenditures to correlate to our new store opening strategy, (v) plans to divest non-core assets to raise non-dilutive capital and (vi) enhancements to its digital offering, including direct-to-consumer delivery and curbside pick-up in light of COVID-19. However, management cannot provide any assurances that we will be successful in accomplishing any of our plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase our need to raise additional capital on an immediate basis. The Company will continually monitor its capital requirements based on its capital and operational needs and the economic environment and may raise new capital as necessary. The Company’s ability to continue as a going concern will depend on its ability to raise additional equity or debt in the private or public markets, reducing operating expenses, divesting of certain non-core assets, and achieving cash flow profitability. While the Company has been successful in raising equity and debt to date, there can be no assurances that the Company will be successful in completing a financing in the future. If the Company is unable to raise additional capital whenever necessary, it may be forced to divest additional assets to raise capital and/or pay down its debt, amend its debt agreements, which could potentially have a dilutive effect on the Company’s shareholders, further reduce operating expenses and temporarily pause the opening of new store locations. Furthermore, COVID-19 and the impact the global pandemic has had and will continue to have on the broader retail environment could also have a significant impact on the Company’s financial operations. COVID-19 The COVID-19 pandemic promoted various recommendations and safety measures from governmental authorities to try and limit the pandemic. The response of governmental authorities is having a significant impact on the private sector and individuals, including unprecedented business, employment and economic disruptions. During the current reporting period, aspects of the Company’s business continue to be affected by the COVID-19 pandemic, with the Company’s offices and retail stores operating within local rules and regulations. While the ultimate severity of the outbreak and its impact on the economic environment is uncertain, the Company is monitoring this closely. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liability. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus. Emerging Growth Company The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act under which emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Functional Currency The Company and its subsidiaries’ functional currency, as determined by management, is the United States (“U.S.”) dollar. These unaudited interim Condensed Consolidated Financial Statements are presented in U.S. dollars as this is the primary economic environment of the group. All references to “C$” refer to Canadian dollars. Significant Accounting Policies The significant accounting policies and critical estimates applied by the Company in these unaudited interim Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in Item 13 of the registration statement on Form 10 for the fiscal year ended June 27, 2020, unless otherwise disclosed in these accompanying notes to the unaudited interim Condensed Consolidated Financial Statements for the nine months ended March 27, 2021. Restricted Cash Restricted cash balances are those which meet the definition of cash and cash equivalents but are not available for use by the Company. As of March 27, 2021 and June 27, 2020, restricted cash was $730 and $1,029, respectively, which is used to pay for lease costs and costs incurred related to building construction in Reno, Nevada. This account is managed by a contractor and the Company is required to maintain a certain minimum balance. Down-Round Features The Company calculates down-round features under Accounting Standards Update (“ASU”) No. 2017-11 (“ASU 2017-11”), “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features” Allocation of Interest to Discontinued Operations Under ASC 205-20 “ Discontinued Operations Note 24 – Discontinued Operations Loss per Share The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, DSU, restricted stock grants, warrants and stock options issued. Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments” In January 2017, the FASB issued ASU No. 2017-04 “Intangibles— Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” In August 2018, the FASB issued ASU 2018-13, “ Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement Recently Issued Accounting Standards In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes (Topic 740)”, In January 2020, the FASB issued ASU 2020-01, “ Investments – Equity Securities (Topic 321) Investments – Equity Method and Joint Ventures (Topic 323) Derivatives and Hedging (Topic 815) In August 2020, the FASB issued ASU 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible instruments and contracts in an Entity’s Own Equity

INVENTORIES

INVENTORIES	9 Months Ended
	Mar. 27, 2021
Inventory Disclosure [Abstract]
Note 3. INVENTORIES	3. INVENTORIES As of March 27, 2021 and June 27, 2020, inventory consists of the following: March 27, June 27, 2021 2020 Raw Materials $ 965,641 $ 1,790,050 Work-in-Process 4,760,097 6,229,152 Finished Goods 11,321,882 10,957,776 Total Inventory $ 17,047,620 $ 18,976,978 During the three months ended March 27, 2021, the Company recognized an impairment of approximately $1,714,000 to write down inventory to its net realizable value.

OTHER CURRENT ASSETS

OTHER CURRENT ASSETS	9 Months Ended
	Mar. 27, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Note 4. OTHER CURRENT ASSETS	4. OTHER CURRENT ASSETS As of March 27, 2021 and June 27, 2020, other current assets consist of the following: March 27, June 27, 2021 2020 Investments $ 3,036,791 $ 3,786,791 Excise Tax Receivable - 5,254,595 Note Receivable (1) 1,670,038 - Other Current Assets 3,470,374 64,071 Total Other Current Assets $ 8,177,203 $ 9,105,457 (1) See “Note 5 – Assets Held for Sale” for further information. As of March 27, 2021 and June 27, 2020, investments included in other current assets consist of the following: The Hacienda Old Pal Other Investments TOTAL Fair Value as of June 27, 2020 $ 750,000 $ 1,970,000 $ 1,066,791 $ 3,786,791 Settlement of Liabilities (750,000 ) - - (750,000 ) Fair Value as of March 27, 2021 $ - $ 1,970,000 $ 1,066,791 $ 3,036,791 In August 2020, the Company entered into an agreement to exchange all of its investment in The Hacienda Company, LLC to settle outstanding balances totaling approximately $750,000. As of March 27, 2021, the Company’s investment balance in The Hacienda Company, LLC was nil. The Company determined that the fair value of its investment in Old Pal LLC was $1,970,000 as of March 27, 2021. The fair value of investments included in other current assets is considered a Level 3 categorization in the fair value hierarchy. Investments are measured at fair value using a market approach that is based on unobservable inputs.

ASSETS HELD FOR SALE

ASSETS HELD FOR SALE	9 Months Ended
	Mar. 27, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Note 5. ASSETS HELD FOR SALE	5. ASSETS HELD FOR SALE A reconciliation of the beginning and ending balances of assets held for sale for the nine months ended March 27, 2021 is as follows: PharmaCann Assets (1) Available for Sale Subsidiaries (2) Discontinued Operations (3) TOTAL Balance at Beginning of Period $ 212,400 $ 12,066,428 $ 71,849,729 $ 84,128,557 Transferred In - 6,614,986 - 6,614,987 Gain on the Sale of Assets Held for Sale - 10,709,999 - 10,709,999 Proceeds from Sale - (24,750,298 ) - (24,750,298 ) Ongoing Activity from Discontinued Operations - (4,641,116 ) (7,845,258 ) (12,486,373 ) Balance at End of Period $ 212,400 $ - $ 64,004,471 $ 64,216,871 (1) During the year ended June 27, 2020, PharmaCann LLC, (“PharmaCann”) transferred 100% of the membership interests for MME Evanston Retail, LLC (“Evanston”), PharmaCann Virginia, LLC (“Staunton”), and PC 16280 East Twombly LLC (“Hillcrest”). As of March 27, 2021, the Company has 100% of membership interests in Staunton which holds land and a license for a vertically-integrated facility in Staunton, Virginia. The Staunton land and license were classified as assets held for sale in accordance with ASC 360, “Long-Lived Assets Classified as Held for Sale” (“ASC 360”) and are measured at the lower of its carrying amount or fair value less costs to sell (“FVLCTS”) which was determined as $212,400 and $0, respectively, as of March 27, 2021. (2) Long-lived assets classified as held for sale that do not qualify as discontinued operation and classified as held for sale. Significant classes of assets and liabilities are presented in the notes to the unaudited interim Condensed Consolidated Financial Statements in accordance with ASC 360-10, “Impairment and Disposal of Long-Lived Assets” (“ASC 360-10”). (3) See “Note 24 - Discontinued Operations” for further information. During the nine months ended March 27, 2021, the Company agreed to transfer all outstanding membership interests in MME Evanston Retail, LLC (“Evanston”), for a dispensary operation located in Evanston, Illinois, to an unaffiliated third party (“Purchaser”). The Company received an aggregate consideration of $20,000,000, of which, $10,000,000 cash was received at closing on July 1, 2020 (“Closing Date”), an additional $8,000,000 cash was received on November 17, 2020 and an additional $2,000,000 in the form of a secured promissory note payable three months following the Closing Date in exchange for all of the Company’s membership interests in Evanston. As of March 12, 2021 (“Amendment Date”), the secured promissory note was amended to waive any default arising from non-payment of principal and interest prior to the Amendment Date if Purchaser pays principal of $1,000,000 and all accrued interest of 2% per annum through the Amendment Date. Interest will accrue at 9% per annum following the Amendment Date. As of March 27, 2021, the Company received cash payment in accordance with the amended secured promissory noted. On August 10, 2020 (“Effective Date”), all operational control and risk of loss was transferred to the Purchaser and the Company had no further obligation to fund operations of Evanston through a Consulting Agreement. Management performed an assessment and determined that the Company no longer has a controlling financial interest as of the Effective Date. The transfer of the cannabis license is pending regulatory approval as of the issuance of these unaudited interim Condensed Consolidated Financial Statements and the Company will take all commercially reasonable steps to maintain all permits for Evanston to operate its business. The Company recognized a gain upon sale of membership interests of $12,415,479 for the difference between the aggregate consideration and the book value of the assets as of the disposition date, less direct costs to sell, which is recognized on the unaudited interim Condensed Consolidated Statements of Operations during the nine months ended March 27, 2021. During the nine months ended March 27, 2021, the Company decided to divest two cannabis licenses and entered into separate agreements to sell 100% of its membership interests in these two locations, located in California. On June 26, 2020, the Company entered into a non-binding term sheet for the retail location located in Seaside, California for an aggregate sales price of $1,500,000 wherein $750,000 is to be paid upon the date of close in addition to $750,000 paid in equal monthly installments over twelve months through a promissory note. The transaction closed in October 2020 and the Company transferred all outstanding membership interests in PHSL, LLC. Upon deconsolidation, the Company will not have any continuing involvement with the former subsidiary. The Company recognized a loss upon sale of membership interests of $332,747 for the difference between the aggregate consideration and the book value of the assets as of the disposition date, less direct costs to sell, which is recognized on the unaudited interim Condensed Consolidated Statements of Operations during the nine months ended March 27, 2021. In December 2020, the Company entered into a purchase agreement for the sale of its membership interests in a retail operation located in Grover Beach, California. The Company received an aggregate consideration of $3,750,000 in which $3,500,000 cash was received thirty days following the closing on March 5, 2021, an additional equity consideration equal to $250,000 was recognized as a gain upon sale of membership interests for a total gain of $255,391 for the difference between the aggregate consideration and the book value of the assets as of the disposition date, less direct costs to sell, which is recognized on the unaudited interim Condensed Consolidated Statements of Operations during the three and nine months ended March 27, 2021.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Mar. 27, 2021
Property, Plant and Equipment [Abstract]
Note 6. PROPERTY AND EQUIPMENT	6. PROPERTY AND EQUIPMENT As of March 27, 2021 and June 27, 2020, property and equipment consists of the following: March 27, June 27, 2021 2020 Land and Buildings $ 37,421,326 $ 37,400,378 Finance Lease Right-of-Use Assets 9,124,138 26,074,429 Furniture and Fixtures 12,428,701 12,393,369 Leasehold Improvements 59,551,369 56,026,595 Equipment and Software 25,823,935 25,379,767 Construction in Progress 28,866,937 36,833,422 Total Property and Equipment 173,216,406 194,107,960 Less Accumulated Depreciation (39,039,417 ) (30,484,865 ) Property and Equipment, Net $ 134,176,989 $ 163,623,095 Depreciation expense related to continuing operations of $3,540,369 and $12,116,847 was recorded for the three and nine months ended March 27, 2021, respectively, of which $42,452 and $383,618, respectively, is included in cost of goods sold. Depreciation expense related to continuing operations of $3,680,139 and $13,331,921 was recorded for the three and nine months ended March 28, 2020, respectively, of which $536,729 and $1,640,176, respectively, is included in cost of goods sold. The amount of depreciation recognized for the right of use assets for capital leases during the three and nine months ended March 27, 2021 was $438,557 and $835,497, respectively, see “Note 11 – Leases” During the three and nine months ended March 28, 2020, borrowing costs totaling $2,106,988 and $4,415,716, respectively, were capitalized using an average capitalization rate of 13.7% and 15.1%, respectively. Borrowing costs were not capitalized as there were no active construction projects in progress during the three and nine months ended March 27, 2021. In addition, during the three and nine months ended March 27, 2021, total labor related costs of $52,351 and $559,515, respectively, were capitalized to Construction in Progress, of which $6,992 and $155,378, respectively, was share-based compensation. In addition, during the three and nine months ended March 28, 2020, total labor related costs of $137,558 and $913,627, respectively, were capitalized to Construction in Progress, of which $19,475 and $192,130, respectively, was share-based compensation.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Mar. 27, 2021
Investments, Debt and Equity Securities [Abstract]
Note 7. INTANGIBLE ASSETS	7. INTANGIBLE ASSETS As of March 27, 2021 and June 27, 2020, intangible assets consist of the following: March 27, June 27, 2021 2020 Dispensary Licenses $ 118,881,616 $ 125,565,281 Customer Relationships 15,927,600 15,927,600 Management Agreement 7,594,937 7,594,937 Capitalized Software 9,343,352 9,255,026 Intellectual Property 6,276,955 8,520,121 Total Intangible Assets 158,024,460 166,862,965 Dispensary Licenses (20,685,860 ) (15,860,670 ) Customer Relationships (14,210,226 ) (6,261,515 ) Management Agreement (715,761 ) (565,972 ) Capitalized Software (4,071,756 ) (2,273,432 ) Intellectual Property (3,006,772 ) (5,496,231 ) Less Accumulated Amortization (42,690,375 ) (30,457,820 ) Intangible Assets, Net $ 115,334,085 $ 136,405,145 The Company recorded amortization expense related to continuing operations of $4,452,573 and $13,104,322 for the three and nine months ended March 27, 2021, respectively. The Company recorded amortization expense related to continuing operations of $4,333,212 and $10,660,164 for the three and nine months ended March 28, 2020, respectively. During the three months ended March 27, 2021, the Company recorded impairment on an intellectual property asset in the amount of $1,573,563. During the three and nine months ended March 27, 2021, $24,832 and $62,951, respectively, of share-based compensation was capitalized to capitalized software. During the three and nine months ended March 28, 2020, $41,293 and $313,535, respectively, of share-based compensation was capitalized to capitalized software.

OTHER ASSETS

OTHER ASSETS	9 Months Ended
	Mar. 27, 2021
Other Income and Expenses [Abstract]
Note 8. OTHER ASSETS	8. OTHER ASSETS As of March 27, 2021 and June 27, 2020, other assets consist of the following: March 27, June 27, 2021 2020 Long-Term Security Deposits for Leases $ 4,817,042 $ 8,177,871 Loans and Other Long-Term Deposits 7,808,326 7,568,738 Other Assets 5,593 53,648 Total Other Assets $ 12,630,961 $ 15,800,257

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	9 Months Ended
	Mar. 27, 2021
Payables and Accruals [Abstract]
Note 9. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	9. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES As of March 27, 2021 and June 27, 2020, accounts payable and accrued liabilities consist of the following: March 27, June 27, 2021 2020 Accounts Payable $ 32,203,779 $ 54,916,904 Accrued Liabilities 14,889,269 10,404,629 Other Accrued Liabilities 10,994,206 10,103,628 Total Accounts Payable and Accrued Liabilities $ 58,087,254 # $ 75,425,161

OTHER CURRENT LIABILITIES

OTHER CURRENT LIABILITIES	9 Months Ended
	Mar. 27, 2021
Retirement Benefits [Abstract]
Note 10. OTHER CURRENT LIABILITIES	10. OTHER CURRENT LIABILITIES As of March 27, 2021 and June 27, 2020, other current liabilities consist of the following: March 27, June 27, 2021 2020 Accrued Interest Payable $ 790,906 $ 9,051,650 Contingent Consideration 87,893 8,951,801 Derivatives 5,707,715 546,076 Other Current Liabilities 14,135,611 1,728,854 Total Other Current Liabilities $ 20,722,125 $ 20,278,381 Contingent Consideration Contingent consideration recorded relates to a business acquisition during the year ended June 27, 2020. The contingent consideration related to the acquisition of One Love Beach Club is based upon fair value of the additional shares required to be paid upon the expiration of the lock-up and is based upon the fair market value of the Company’s trading stock and is considered a Level 1 categorization in the fair value hierarchy. Contingent consideration classified as a liability and measured at fair value in accordance with ASC 480, “Distinguishing Liabilities from Equity” Derivative Liabilities During the three months ended March 27, 2021, the Company issued the 50,000,000 warrants related to a private placement. The exercise price of the warrants is denominated in Canadian dollars. See “ Note 14 - Shareholders’ Equity – Private Placement “Derivatives and Hedging” The following are the warrants issued related to the financing transactions that were accounted for as derivative liabilities: Number of Warrants September Bought Deal Equity Financing 7,840,909 December Bought Deal Equity Financing 13,640,000 March 2021 Private Placement 50,000,000 (1) (2) 71,480,909 (1) During the three months ended March 27, 2021, the Company issued 50,000,000 warrants for Subordinate Voting Shares with an exercise price of C$0.50 per warrant and an expiration date of March 27, 2024. The exercise price of the warrants was denominated in a price other than the Company’s functional currency. In accordance with ASC 815, a share warrant denominated in a price other than the functional currency of the Company fails to meet the definition of equity. Accordingly, such a contract or instrument would be accounted for as derivative liabilities and measured at fair value with changes in fair value recognized in the unaudited interim Condensed Consolidated Statements of Operations at each period-end. (2) See “Note 14 - Shareholders’ Equity – Private Placement” for further information. A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the nine months ended March 27, 2021 is as follows: March 27, 2021 Balance at Beginning of Period $ 546,076 Initial Recognition of Derivative Liabilities 7,228,134 Change in Fair Value of Derivative Liabilities (2,066,495 ) Balance at End of Period $ 5,707,715 The fair value of the September and December bought deal warrants was measured based on Level 1 inputs on the fair value hierarchy since there are quoted prices in active markets for these warrants. The Company used the closing price of the publicly-traded warrants to estimate fair value of the derivative liability as of March 27, 2021 for those warrants. The fair value of the March 2021 private placement warrants was measured based on Level 3 inputs on the fair value hierarchy using the Black-Scholes Option pricing model using the following variables: Expected Stock Price Volatility 90.01 % Risk-Free Annual Interest Rate 0.06 % Expected Life 1.00 Share Price 0.33 Exercise Price 0.40

LEASES

LEASES	9 Months Ended
	Mar. 27, 2021
Leases [Abstract]
Note 11. LEASES	11. LEASES In accordance with ASU 2016-02 “Leases”, the Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets and accrued obligations under operating lease (current and non-current) liabilities in the unaudited interim Condensed Consolidated Balance Sheets. Finance lease ROU assets are included in property and equipment, net and accrued obligations under finance lease (current and noncurrent) liabilities in the unaudited interim Condensed Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are classified as a finance lease or an operating lease. The Company classifies a lease as an operating lease when it does not meet any of the criteria of a finance lease as set forth by ASU 2016-02. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Most operating leases contain renewal options that provide for rent increases based on prevailing market conditions. The Company has lease extension terms at its properties that have either been extended or are likely to be extended. The terms used to calculate the ROU assets for these properties include the renewal options that the Company is reasonably certain to exercise. The below are the details of the lease cost and other disclosures regarding the Company’s leases for the three and nine months ended March 27, 2021 and March 28, 2020: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Finance Lease Cost: Amortization of Finance Lease Right-of-Use Assets $ 438,557 $ 586,376 $ 835,497 $ 3,203,300 Interest on Lease Liabilities 2,077,724 1,635,017 4,061,842 4,617,716 Operating Lease Cost 7,512,753 6,377,596 20,935,916 19,076,003 Total Lease Expenses $ 10,029,034 $ 8,598,989 $ 25,833,255 $ 26,897,019 2021 2020 2021 2020 Gain on Sale and Leaseback Transactions, Net $ - $ - $ - $ (704,207 ) Cash Paid for Amounts Included in the Measurement of Lease Liabilities: Financing Cash Flows from Finance Leases $ - $ 509,844 $ - $ 807,432 Operating Cash Flows from Operating Leases $ 1,712,630 $ 1,625,567 $ 15,611,252 $ 16,892,734 Non-Cash Additions to Right-of-Use Assets and Lease Liabilities: Recognition of Right-of-Use Assets for Finance Leases $ - $ - $ - $ 45,614,041 Recognition of Right-of-Use Assets for Operating Leases $ - $ 8,131,728 $ - $ 144,602,158 The weighted-average remaining lease term and discount rate related to the Company’s finance lease liabilities as of March 27, 2021 were 48 years and 17.77%, respectively. The weighted-average remaining lease term and discount rate related to the Company’s operating lease liabilities as of March 27, 2021 were 5 years and 10.25%, respectively. The Company’s lease discount rates are generally based on estimates of its incremental borrowing rate, as the discount rates implicit in the Company’s leases cannot be readily determined. Future lease payments under non-cancellable operating leases and finance leases as of March 27, 2021 are as follows: Fiscal Year Ending Operating Leases Finance Leases June 26, 2021 $ 5,504,585 $ 1,302,684 June 25, 2022 22,989,719 5,324,591 June 24, 2023 23,241,907 5,484,327 June 29, 2024 27,249,872 9,860,306 June 28, 2025 21,096,035 6,522,077 Thereafter 102,173,727 1,076,074,995 Total Lease Payments 202,255,845 1,104,568,980 Less Interest (96,771,980 ) (1,075,923,388 ) Present Value of Lease Liability $ 105,483,865 $ 28,645,592 Finance leases noted above contain required security deposits, refer to “Note 8 – Other Assets” Lease Deferral Arrangements During the nine months ended March 27, 2021, the Company modified its existing lease arrangements with the Treehouse Real Estate Investment Trust (the “REIT”) in which the REIT agreed to defer a portion of total current monthly base rent on certain cultivation facilities and ground leases for the 36-month period between July 1, 2020 and July 1, 2023 for a total of fourteen properties. Amendments for eight of the properties were accounted for as lease modifications in accordance with ASC 842, “ Leases Debt Note 12 – Notes Payable

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Mar. 27, 2021
Debt Disclosure [Abstract]
Note 12. NOTES PAYABLE	12. NOTES PAYABLE As of March 27, 2021 and June 27, 2020, notes payable consist of the following: March 27, June 27, 2021 2020 Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum. $ 83,400,000 $ 83,576,661 Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on January 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum. 104,436,180 77,675,000 Convertible debentures dated between September 16, 2020 and December 17, 2020, issued to accredited investors and qualified institutional buyers, which mature two years from issuance, and bear interest at a rate of 7.5% per annum. 5,000,000 - Promissory notes dated between January 15, 2019 through March 29, 2019, issued for deferred payments on acquisitions, which mature on varying dates from July 31, 2021 to April 1, 2022 and bear interest at rates ranging from 8.0% to 9.0% per annum. 3,762,500 16,173,250 Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471. 2,233,720 2,339,564 Other 15,418 15,418 Total Notes Payable 198,847,818 179,779,893 Less Unamortized Debt Issuance Costs and Loan Origination Fees (8,832,434 ) (10,781,288 ) Net Amount $ 190,015,384 $ 168,998,605 Less Current Portion of Notes Payable (97,169,640 ) (16,188,668 ) Notes Payable, Net of Current Portion $ 92,845,744 $ 152,809,937 A reconciliation of the beginning and ending balances of notes payable for the nine months ended March 27, 2021 is as follows: Balance at Beginning of Period $ 168,998,605 Cash Additions 15,830,279 Non-Cash Addition - Debt Modification 877,439 Debt Discount Recognized on Modification (977,370 ) Extinguishment of Debt (12,173,250 ) Paid-In-Kind Interest Capitalized 15,178,462 Cash Payments (660,094 ) Equity Component of Debt- New and Amended (5,583,407 ) Cash Paid for Debt Issuance Costs 99,931 Accretion of Debt Discount included in Discontinued Operations 5,834,043 Accretion of Debt Discount 2,590,746 Balance at End of Period $ 190,015,384 Less Current Portion of Notes Payable (97,169,640 ) Notes Payable, Net of Current Portion $ 92,845,744 Amendments to Senior Secured Term Loan Facility On July 2, 2020, the Company completed the amendment of its existing term loan facility (the “Facility”) in the principal amount of $77,675,000 with funds managed by Hankey Capital and with an affiliate of Stable Road Capital (the “Lenders”) wherein the entirety of the interest at a rate of 15.5% per annum shall accrue monthly to the outstanding principal as payment-in-kind effective March 1, 2020 through July 2, 2021. Thereafter until maturity on January 31, 2022, one-half of the interest (7.75% per annum) shall be payable monthly in cash and one-half of the interest (7.75% per annum) shall be paid-in-kind. In addition, the Company may request an increase to the Facility through December 31, 2020 to be funded through incremental term loans. Certain reporting and financial covenants were added, and the minimum liquidity covenant was waived until September 30, 2020 wherein the amount of required cash balance thereafter was amended. The amendment to the Facility was not deemed to be a substantial modification under ASC 470-50, “Modifications and Extinguishments” The Company incurred an amendment fee of $834,000 that was added to the outstanding principal balance. As consideration for the amendment to the Facility, the Company issued approximately 20,227,863 warrants exercisable at $0.34 per share until July 2, 2025. The Company also cancelled 20,227,863 existing warrants held by the lenders exercisable at $0.60 per share until December 31, 2022. The warrants may be exercised at the election of their holders on a cashless basis. The warrants issued in connection with the term loan facility met the scope exception under ASC 815 and are classified as equity instruments. The change in fair value of the warrants was recorded as a debt discount in connection with the Facility. As a result of the modification, the Company recorded an additional debt discount of $906,436 related to the change in terms of the warrants. See “Note 15 – Share-Based Compensation” On September 16, 2020, the Company entered into further amendments wherein the amount of funds available under the Facility was increased by $12,000,000, of which $5,700,000 was fully committed by the lenders through October 31, 2020. The additional amounts are funded through incremental term loans at an interest rate of 18.0% per annum wherein 12.0% shall be paid in cash monthly in arrears and 6.0% shall accrue monthly as payment-in-kind. In connection with each incremental draw under the amended Facility, the Company shall issue warrants equal to 200% of the incremental term loan amount, divided by the greater of (a) $0.20 per share and (b) 115% multiplied by the volume-weighted average trading price (“VWAP”) of the shares for the five consecutive trading days ending on the trading day immediately prior to the applicable funding date of the second tranche, which shall be the exercise price of the issued warrant. Such warrants are subject to a down round feature wherein the exercise price would be decreased in the event of the exercise of a down-round price reset of select warrants under the senior secured convertible credit facility with Gotham Green Partners (“GGP”). Refer to “ Note 13 – Senior Secured Convertible Credit Facility On September 16, 2020, the Company closed on an incremental term loan of $3,000,000 under the amended Facility and issued 30,000,000 warrants with an exercise price of $0.20 per share until September 16, 2025. On October 30, 2020, the Company closed on an incremental term loan of $7,705,279 under the amended Facility and issued 77,052,790 warrants with an exercise price of $0.20 per share until September 14, 2025. The warrants may be exercised at the election of their holders on a cashless basis and are classified as equity instruments. See “Note 15 – Share-Based Compensation” On September 16, 2020 and September 28, 2020, the down round feature on the warrants issued in connection with the incremental term loan of $3,000,000 on September 16, 2020 was triggered wherein the exercise price was adjusted to $0.17 and $0.15 per share, respectively. The value of the effect of the down round feature was determined to be $405,480 and recognized as an increase in additional paid-in capital. Amendment to Promissory Note On February 25, 2021, the Company completed the second amendment of its existing promissory note in the principal amount of $3,500,000 issued in connection with the acquisition of Viktoriya’s Medical Supplies LLC d/b/a Buddy’s Cannabis wherein the maturity date was amended to the earlier of April 1, 2022 or in the event of default. In conjunction with the amendment to promissory note, the Company issued Subordinate Voting Shares in the aggregate amount of $2,000,000 to the lender. The balance of the promissory note will bear interest at a rate of 9.0% per annum and be paid monthly commencing on May 1, 2021 until the amended maturity date. The second amendment to the existing promissory note was deemed to be a substantial modification under ASC 470-50 and a loss on extinguishment of $2,410,504 was recorded in the unaudited interim Condensed Consolidated Statements of Operations for the three and nine months ended March 27, 2021. Acquisition Promissory Note During the three months ended March 27, 2021, as a result of the legal proceedings and decisions by the applicable governing bodies, the Company derecognized an acquisition promissory note and its accrued interest in the aggregate amount of $13,375,430 and recorded a gain on disposal of assets for the same amount which is recorded as a component of net (income) loss from discontinued operations for the three and nine months ended March 27, 2021. Refer to the May 2020 litigation disclosed in “ Note 21 – Commitments and Contingences Unsecured Convertible Facility On September 16, 2020, the Company entered into an unsecured convertible debenture facility for total available proceeds of $10,000,000 wherein the convertible debentures shall have a conversion price equal to the closing price on the trading day immediately prior to the closing date, a maturity date of 24 months from the date of issuance and will bear interest at a rate of 7.5% per annum payable semi-annually in cash. The unsecured facility is callable in additional tranches in the amount of $1,000,000 each, up to a maximum of $10,000,000 under all tranches. The timing of additional tranches can be accelerated based on certain conditions. The Company has the right to prepay, in whole or in part, the outstanding principal amount and accrued interest prior to maturity, upon payment of 7.5% of the principal amount being repaid, less the amount of interest paid during the year of prepayment. The debentures provide for the automatic conversion into Subordinate Voting Shares in the event that the VWAP is greater than $0.25 on the CSE for 45 consecutive trading days, at a conversion price per Subordinate Voting Share equal to $0.17. On September 16, 2020, the Company closed on an initial $1,000,000 of the facility with a conversion price of $0.17 per Subordinate Voting Share. In connection with the initial tranche, the Company issued 3,293,413 warrants with an exercise price of $0.21 per share. On September 28, 2020, the Company closed on a second tranche of $1,000,000 under its existing unsecured convertible facility with a conversion price of $0.15 per Subordinate Voting Share. In connection with the second tranche, the Company issued 3,777,475 warrants with an exercise price of $0.17 per Subordinate Voting Share. On November 20, 2020, the Company closed on a third tranche of $1,000,000 under the facility with a conversion price of $0.15 per Subordinate Voting Share. In connection with the third tranche, the Company issued 3,592,425 warrants with an exercise price of $0.17 per share. On December 17, 2020, the Company closed on a fourth tranche of $1,000,000 under the facility with a conversion price of $0.15 per Subordinate Voting Share. In connection with the fourth tranche, the Company issued 3,597,100 warrants with an exercise price of $0.18 per share. On January 29, 2021, the Company closed on a fifth tranche of $1,000,000 under its existing unsecured convertible facility with a conversion price of $0.16 per Subordinate Voting Share. In connection with the fifth tranche, the Company issued 3,355,000 warrants with an exercise price of $0.19 per share. Under ASC 815, the conversion option and warrants were recorded as an equity instrument. As of March 27, 2021, the relative fair value of the warrants with a value of $799,949 has been recorded to equity. On February 10, 2021, the Company entered into an agreement with Wicklow Capital, a related party, to issue additional warrants for Subordinate Voting Shares within 12 months based on the borrowed amount of the unsecured convertible facility tranches. These warrants will consist of 644,068, 761,205, 775,510, 741,260, and 693,575 warrants with an exercise price of $0.21, $0.18, $0.17, $0.18, and $0.19, respectively. The commitment to issue warrants related to the existing unsecured convertible facility was deemed to be a substantial modification of the facility under ASC 470-50 and a loss on extinguishment of $4,010,022 was recorded in the unaudited interim Condensed Consolidated Statements of Operations for the three and nine months ended March 27, 2021. Financing Liability In connection with the Company’s failed sale and leaseback transactions described in “Note 11 – Leases”

SENIOR SECURED CONVERTIBLE CRED

SENIOR SECURED CONVERTIBLE CREDIT FACILITY	9 Months Ended
	Mar. 27, 2021
Risks and Uncertainties [Abstract]
Note 13. SENIOR SECURED CONVERTIBLE CREDIT FACILITY	13. SENIOR SECURED CONVERTIBLE CREDIT FACILITY As of March 27, 2021 and June 27, 2020, senior secured convertible credit facility consists of the following: March 27, June 27, Tranche 2021 2020 Senior secured convertible notes dated April 23, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 1A $ 20,674,403 $ 21,660,583 Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 1B 89,039,556 86,053,316 Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 2 28,953,899 26,570,948 Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 3 11,211,533 10,288,815 Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 4 13,609,724 12,500,000 Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 21,165,550 19,423,593 Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. IA-1 2,959,951 2,734,282 Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. IA-2 5,724,068 - Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 8,513,121 8,199,863 Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 1,979,156 - Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 11,131,939 - Total Drawn on Senior Secured Convertible Credit Facility 214,962,900 187,431,400 Less Unamortized Debt Discount (57,897,490 ) (21,062,937 ) Senior Secured Convertible Credit Facility, Net $ 157,065,410 $ 166,368,463 A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the nine months ended March 27, 2021 is as follows: Tranche 1 Tranche 2 Tranche 3 Tranche 4 Incremental Advance - 1 Incremental Advance - 2 3rd Advance Amendment Restatement Fee Notes 2nd Restatement Fee Notes TOTAL Balance as of June 27, 2020 $ 102,833,447 $ 25,352,687 $ 9,680,433 $ 286,691 $ 2,168,540 $ - $ - $ 18,964,600 $ 7,082,065 $ - 166,368,463 Cash Additions - - - - - 5,420,564 10,937,127 - - - 16,357,691 Repayments (8,000,000 ) - - - - - - - - - (8,000,000 ) Principal Reallocation 585,058 (3,276 ) (1,277 ) (404,451 ) (340 ) (589 ) - (2,395 ) (24,084 ) (148,646 ) - Fees Capitalized to Debt Related to - - - - - (468,564 ) (937,127 ) - - - (1,405,691 ) Paid-In-Kind Interest Capitalized 9,396,021 2,386,229 923,996 1,115,478 226,009 303,299 194,812 1,744,352 736,039 127,802 17,154,037 Net Effect on Debt from Extinguishment 4,812,996 962,750 497,175 2,167,870 (453,979 ) - - 455,792 630,758 2,000,000 11,073,362 Equity Component Debt - New (23,562,662 ) (6,147,968 ) (2,480,673 ) (2,839,499 ) (1,296,844 ) (3,239,507 ) (7,694,405 ) (4,337,438 ) (4,551,977 ) - (56,150,973 ) Cash Paid for Debt Issuance Costs - - - - - (175,000 ) (200,000 ) - - - (375,000 ) Amortization of Debt Discounts 5,394,019 1,282,359 531,455 1,057,893 414,622 726,545 565,258 971,013 1,099,158 1,198 12,043,520 Balance as of March 27, 2021 $ 91,458,879 $ 23,832,781 $ 9,151,109 $ 1,383,982 $ 1,058,008 $ 2,566,748 $ 2,865,665 $ 17,795,924 $ 4,971,959 $ 1,980,354 $ 157,065,410 On July 2, 2020, the Company amended and restated the securities purchase agreement with Gotham Green Partners (“GGP”) under the senior secured convertible credit facility (the “Convertible Facility”) (the “Fourth Amendment”) wherein the minimum liquidity covenant was waived until September 30, 2020 and resetting at $5,000,000 thereafter with incremental increases on March 31, 2021 and December 31, 2021. The payment-in-kind feature on the Convertible Facility was also extended, such that 100% of the cash interest due prior to June 2021 will be paid-in-kind and 50% of the cash interest due thereafter will be paid-in-kind. The Fourth Amendment released certain assets from its collateral to allow greater flexibility to generate proceeds through the sale of non-core assets. The Fourth Amendment allows for immediate prepayment of amounts under the Convertible Facility with a 5% prepayment penalty until 2nd anniversary of the Fourth Amendment and 3% prepayment penalty thereafter. As part of the Fourth Amendment, holders of notes under the Convertible Facility were provided down-round protection where issuances of equity interests (including securities that are convertible or exchangeable for equity interests) by the Company at less than the higher of (i) lowest conversion price under the amended and restated notes of the Convertible Facility amendment dated March 27, 2020 and (ii) the highest conversion price determined for any incremental advances, will automatically adjust the conversion/exercise price of the previous tranches and incremental tranche 4 warrants and the related replacement warrants to the price of the newly issued equity interests. Certain issuances of equity interests are exempted such as issuances to existing lenders, equity interests in contemplation at the time of Fourth Amendment and equity interests issued to employees, consultants, directors, advisors or other third parties, in exchange for goods and services or compensation. Pursuant to ASU 2017-11, the down-round protection was not considered a derivative and will be recognized when the down-round protection adjustments are triggered. As consideration for the amendment, the conversion price for 52% of the tranches 1 through 3 and the first amendment fee notes outstanding under the Convertible Facility were amended to $0.34 per share. An amendment fee of $2,000,000 was also paid through the issuance of additional notes at a conversion price of $0.28 per share. The Fourth Amendment to the Convertible Facility was deemed to be a substantial modification under ASC 470-50 and a loss on extinguishment of $10,129,655 was recorded in the unaudited interim Condensed Consolidated Statements of Operations for the nine months ended March 27, 2021. On September 14, 2020, the Company closed on an incremental advance in the amount of $5,000,000 under its existing Convertible Facility with GGP at a conversion price of $0.20 per share. In connection with the incremental advance, the Company issued 25,000,000 warrants with an exercise price of $0.20 per share. In addition, 1,080,255 existing warrants were cancelled and replaced with 16,875,001 warrants with an exercise price of $0.20 per share. Pursuant to the terms of the GGP Facility, the conversion price for 5.0% of the existing Notes outstanding prior to Tranche 4 and Incremental Advance (including paid-in-kind interest accrued on such Notes), being 5.0% of an aggregate principal amount of $170,729,923, was amended to $0.20 per share. As consideration for the additional advance, the Company issued convertible notes as consideration for a $468,564 fee with a conversion price of $0.20 per share. On September 16, 2020 and September 28, 2020, the down round feature on the convertible notes and warrants issued in connection with Tranche 4, Incremental Advances and certain amendment fees was triggered wherein the exercise price was adjusted to $0.17 and $0.15 per share, respectively. The value of the effect of the down round feature on convertible notes and warrants was determined to be $32,744,770 and $6,723,954, respectively, for the nine months ended March 27, 2021. The effect related to convertible notes was recognized as additional debt discount and an increase in additional paid-in-capital. The effect related to warrants was recognized as a deemed distribution and an increase in additional paid-in capital. On November 1, 2020, the Company repaid $8,000,000 of borrowings under the Convertible Facility and recorded a loss $943,706 on the partial extinguishment of debt and is included in the net effect on equity component of new and amended debt in the reconciliation of the beginning and ending balances of senior secured convertible credit facility for the nine months ended March 27, 2021. On January 11, 2021, the Company amended and restated the securities purchase agreement under the Convertible Facility (the “Fifth Amendment”) wherein the minimum liquidity covenant was waived until June 30, 2021 and resetting at $7,500,000 effective on July 1, 2021 through December 31, 2021, and $15,000,000 thereafter, and waiver of the minimum liquidity covenant if the Company is current on cash interest. Furthermore, covenants with regards to non-operating leases, capital expenditures and corporate SG&A will now be tied to a board of directors approved budget. In conjunction with the Fifth Amendment, the Company received an additional advance of $10,000,000 under its existing Convertible Facility with GGP with a conversion price of $0.16 per share. The Company also issued 62,174,567 warrants exercisable for five years at a purchase price of $0.16 per share. The notes, restatement fee notes and warrants are subject to down round adjustment provisions, with certain exceptions, if the Company issues securities at a lower price. The Fifth Amendment to the Convertible Facility was not deemed to be a substantial modification under ASC 470-50 . Pursuant to the terms of the GGP Facility, the conversion price of $47,100,000 of the existing Notes outstanding prior to Tranche 4 and Incremental Advance (including paid-in-kind interest accrued on such Notes), of an aggregate principal amount of $168,100,000, was amended to $0.17 per share, of which $16,800,000 of the Notes outstanding will continue to be subject to down round adjustment provisions. In addition, the Company cancelled an aggregate of 2,160,507 warrants that were issued with such notes and, in exchange, issued 41,967,832 warrants with an exercise price of $0.16 per share. In connection with the Fifth Amendment, the Company issued convertible notes as consideration for a $937,127 fee with a conversion price of $0.16 per share.

SHAREHOLDERS EQUITY

SHAREHOLDERS EQUITY	9 Months Ended
	Mar. 27, 2021
MEZZANINE EQUITY:
Note 14. SHAREHOLDERS' EQUITY	14. SHAREHOLDERS’ EQUITY Issued and Outstanding A reconciliation of the beginning and ending issued and outstanding shares is as follows: Subordinate Voting Super MM CAN USA MM Enterprises USA Balance as of June 27, 2020 403,907,218 815,295 236,123,851 725,016 Cancellation of Super Voting Shares - (815,295 ) - - Shares Issued for Cash 57,800,000 - - - Shares Issued to Settle Accounts Payable and Liabilities 14,911,047 - - - Shares Issued for Exercise of Warrants - - 27,164,323 - Redemption of MedMen Corp Redeemable Shares 133,969,228 - (133,969,228 ) - Shares Issued for Vested Restricted Stock Units 7,173,256 - - - Shares Issued for Debt Amendment Fees 4,305,148 - - - Stock Grants for Compensation 3,703,730 - - - Balance as of March 27, 2021 625,769,627 - 129,318,946 725,016 Cancellation of Super Voting Shares Effective as of December 10, 2020, the Company cancelled the remaining 815,295 Class A Super Voting Shares that were granted via proxy to Benjamin Rose wherein no consideration was paid. The effect of the cancellation was recognized as a reduction in the mezzanine equity for the book value of $82,500 and the difference over the repurchase price of nil was recorded to additional paid-in capital. There was no effect on total shareholders’ equity as a result of this cancellation. As of March 27, 2021, there are no outstanding Class A Super Voting Shares. Private Placement Effective as of February 15, 2021, the Company executed the sale of 7,800,000 units through an investor agreement for a purchase price of $0.37 per share or aggregated total proceeds of approximately $2,866,000. Each unit consists of one Class B Subordinate Voting Share and one share purchase warrant. Each warrant permits the holder to purchase one additional Class B Subordinate Voting Share at an exercise price of $0.46 per share for a period of five years from the date of issuance. The warrants were classified within shareholders’ equity as additional-paid-in-capital in accordance with ASC 815-10, “ Derivatives and Hedging Effective as of March 18, 2021, the Company executed the sale (“Private Placement Offering”) of 50,000,000 units (“Private Placement Units”) and 50,000,000 warrants that were granted through a separate private placement for a purchase price of C$0.40 per Private Placement Unit for aggregated total proceeds of approximately C$20,000,000 (or $16,019,597 U.S. dollars). Each Private Placement Unit consisted of one Class B Subordinate Voting Share and one share purchase warrant of the Company (“Private Placement Warrant”). Each Private Placement Warrant entitles the holder to purchase one Subordinate Voting Share at an exercise price of C$0.50 for a period of 3 years following the closing of the Private Placement Offering. See “Note 10 – Other Current Liabilities” Cashless Exercise of Warrants On March 22, 2021, 40,000,000 warrants were exercised on a cashless basis for 27,164,323 MM CAN USA Class B Redeemable Shares. Non-Controlling Interests Non-controlling interest represents the net assets of the subsidiaries that the holders of the Subordinate Voting Shares do not directly own. The net assets of the non-controlling interest are represented by the holders of MM CAN USA Redeemable Shares and the holders of MM Enterprises USA Common Units. Non-controlling interest also represents the net assets of the entities the Company does not directly own but controls through a management agreement. As of March 27, 2021 and June 27, 2020, the holders of the MM CAN USA Redeemable Shares represent approximately 17.13% and 36.89%, respectively, of the Company and holders of the MM Enterprises USA Common Units represent approximately 0.10% and 0.11%, respectively, of the Company. Variable Interest Entities The below information are entities the Company has concluded to be variable interest entities (“VIEs”) as the Company possesses the power to direct activities through management services agreements (“MSAs”). Through these MSAs, the Company can significantly impact the VIEs and thus holds a controlling financial interest. The following table represents the summarized financial information about the Company’s consolidated VIEs. VIEs include the balances of LAX Fund II Group, LLC, Natures Cure, Inc. and Venice Caregiver Foundation, Inc. This information represents amounts before intercompany eliminations. As of and for the nine months ended March 27, 2021, the balances of the VIEs before any intercompany eliminations consists of the following: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,197,557 $ - $ 10,310,942 $ 11,508,499 Non-Current Assets 13,045,511 2,925,798 4,980,057 20,951,366 Total Assets $ 14,243,068 $ 2,925,798 $ 15,290,999 $ 32,459,865 Current Liabilities $ 10,836,220 $ 9,032,248 $ 3,083,532 $ 22,952,000 Non-Current Liabilities 7,827,937 2,386,061 7 10,214,005 Total Liabilities $ 18,664,157 $ 11,418,309 $ 3,083,539 $ 33,166,005 Non-Controlling Interest $ (4,421,089 ) $ (8,492,511 ) $ 12,207,460 $ (706,140 ) Revenues $ 6,457,626 $ - $ 9,911,450 $ 16,369,076 Net Income (Loss) Attributable to Non-Controlling Interest $ 1,504,096 $ (2,422,184 ) $ 5,427,833 $ 4,509,745 As of and for the year ended June 27, 2020, the balances of the VIEs consists of the following: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,233,188 $ 811,025 $ 6,639,231 $ 8,683,444 Non-Current Assets 16,867,824 3,259,563 5,032,428 25,159,815 Total Assets $ 18,101,012 $ 4,070,588 $ 11,671,659 $ 33,843,259 Current Liabilities $ 12,831,161 $ 7,481,953 $ 3,745,710 $ 24,058,824 Non-Current Liabilities 11,196,585 2,662,078 1,146,322 15,004,985 Total Liabilities $ 24,027,746 $ 10,144,031 $ 4,892,032 $ 39,063,809 Non-Controlling Interest $ (5,926,734 ) $ (6,073,443 ) $ 6,779,627 $ (5,220,550 ) Revenues $ 10,949,458 $ - $ 13,976,810 $ 24,926,268 Net Income (Loss) Attributable to Non-Controlling Interest $ (6,132,528 ) $ (3,777,079 ) $ 3,143,437 $ (6,766,170 ) The net change in the consolidated VIEs and other non-controlling interest are as follows for the nine months ended March 27, 2021: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. Other Non- Controlling Interests TOTAL Balance as of June 27, 2020 $ (5,925,185 ) $ (6,070,327 ) $ 6,779,627 $ (331,561,812 ) $ (336,777,697 ) Net Income (Loss) 1,504,096 (2,422,184 ) 5,427,833 (30,614,859 ) (26,105,114 ) Equity Component on Debt and Debt Modification - - - 4,055,133 4,055,133 Deferred Tax Impact On Conversion Feature - - - (1,210,052 ) (1,210,052 ) Redemption of MedMen Corp Redeemable Shares - - - (75,460,832 ) (75,460,832 ) Balance as of March 27, 2021 $ (4,421,089 ) $ (8,492,511 ) $ 12,207,460 $ (434,792,422 ) $ (435,498,562 ) Le Cirque Rouge, LP (the “Operating Partnership,” or the “OP”) is a Delaware limited partnership that holds substantially all of the real estate assets owned by the REIT, conducts the REIT’s operations, and is financed by the REIT. Under ASC 810, “Consolidation” “Note 11 – Leases”

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Mar. 27, 2021
Share-based Payment Arrangement [Abstract]
Note 15. SHARE-BASED COMPENSATION	15. SHARE-BASED COMPENSATION The Company has a stock and equity incentive plan (the “Incentive Plan”) under which the Company may issue various types of equity instruments to any employee, officer, consultant, advisor or director. The types of equity instruments issuable under the Incentive Plan encompass, among other things, stock options, stock grants, and restricted stock grants (together, “Awards”). Stock based compensation expenses are recorded as a component of general and administrative to the extent that the Company has not appointed a Compensation Committee, all rights and obligations under the Incentive Plan shall be those of the full Board of Directors. The maximum number of Awards that may be issued under the Incentive Plan shall be determined by the Compensation Committee or the Board of Directors in the absence of a Compensation Committee. Any shares subject to an Award under the Incentive Plan that are forfeited, canceled, expire unexercised, are settled in cash, or are used or withheld to satisfy tax withholding obligations, shall again be available for Awards under the Incentive Plan. Vesting of Awards will be determined by the Compensation Committee or Board of Directors in the absence of one. The exercise price for Awards (if applicable) will generally not be less than the fair market value of the Award at the time of grant and will generally expire after 10 years. A summary of share-based compensation expense for the three and nine months ended March 27, 2021 and March 28, 2020 is as follows: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Stock Options $ 305,565 $ (69,571 ) $ 2,851,785 $ 2,584,933 LTIP Units - 179,014 - 1,492,073 Stock Grants for Services, Net (63,189 ) 1,151,366 58,043 3,041,012 Restricted Stock Grants - 916,842 437,386 3,727,485 Total Share-Based Compensation $ 242,376 $ 2,177,651 $ 3,347,214 $ 10,845,503 For the nine months ended March 27, 2021 and March 28, 2020, the fair value of stock options granted with a fixed exercise price was determined using the Black-Scholes option-pricing model with the following assumptions at the time of grant: Nine Months Ended March 27, March 28, 2021 2020 Weighted-Average Risk-Free Annual Interest Rate 1.05 % 1.70 % Weighted-Average Expected Annual Dividend Yield 0.0 % 0.0 % Weighted-Average Expected Stock Price Volatility 116.5 % 87.9 % Weighted-Average Expected Life in Years 7.50 7.50 Weighted-Average Estimated Forfeiture Rate 40.0 % 40.0 % Stock Options A reconciliation of the beginning and ending balance of stock options outstanding is as follows: Number of Stock Options Weighted- Balance as of June 27, 2020 8,618,204 $ 2.78 Granted 7,318,669 Forfeited (1,344,375 ) Balance as of March 27, 2021 14,592,498 $ 1.48 Stock Options Exercisable as of March 27, 2021 12,769,339 $ 1.45 The aggregate intrinsic value of options outstanding was nil at both March 27, 2021 and June 27, 2020. LTIP Units and LLC Redeemable Units A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows: Weighted LTIP Units LLC Average Issued and Redeemable Grant Date Outstanding Units Fair Value Balance as of June 27, 2020 and March 27, 2021 19,323,878 725,016 $ 0.52 Deferred Stock Units Effective December 10, 2019, the Company’s board of directors approved a Deferred Share Unit (“DSU”) award under the Company’s Incentive Plan. The DSU award was for units to the Company’s non-management directors. Each director will be provided the Company’s Subordinate Voting Shares based on the duration of their term as a director up to $250,000 for a year of service ending August 2020. As of March 27, 2021, and June 27, 2020, there was nil and 1,283,567 units issued and outstanding, respectively. For the three and nine months ended March 27, 2021, compensation expense related to the DSU award was nil and nil, respectively, was included in accounts payable and stock-based compensation expense on the Company’s unaudited interim Condensed Consolidated Balance Sheets. As of March 27, 2021, the corresponding Subordinate Voting Shares had been issued to the directors. A reconciliation of the beginning and ending balance of DSUs outstanding is as follows: Issued and Outstanding Weighted- Balance as of June 27, 2020 1,283,567 $ 0.38 Settled (1,283,567 ) $ (0.38 ) Balance as of March 27, 2021 - $ - Restricted Stock Grants During the nine months ended March 27, 2021, the Company granted an entitlement to 28,210,512 of restricted Subordinate Voting Shares to certain officers, directors and employees. A reconciliation of the beginning and ending balance of restricted stock grants outstanding is as follows: Issued and Outstanding Vested Weighted- Balance as of June 27, 2020 7,159,164 192,459 $ 0.68 Granted (1) 28,210,512 - $ 0.17 Forfeiture of Restricted Stock (2) (4,240,013 ) - $ (0.20 ) Redemption of Vested Stock (8,107,249 ) (8,107,249 ) $ (0.26 ) Vesting of Restricted Stock - 8,533,485 $ 0.35 Balance as of March 27, 2021 23,022,414 618,695 $ 0.28 (1) Issued on December 11, 2020 to certain officers and employees of the Company and vest 37.5%, 12.5%, 37.5%, 12.5% on the 1st, 2nd, 3rd and 4th anniversary, respectively. (2) 4,240,013 of the restricted stock grants were forfeited upon the resignation of certain employees prior to their vesting. Certain restricted stock granted has vesting which is based on market conditions. For restricted stock that have no market condition vesting, the fair value was determined using the trading value of the Subordinate Voting Shares on the date of grant. For the restricted stock that have market condition vesting, these shares were valued using a Monte Carlo simulation model taking into account the trading value of the Company’s Subordinate Voting Shares on the date of grant and into the future encompassing a wide range of possible future market conditions. During the nine months ended March 27, 2021, there were no restricted stock grants with a market vesting condition. Warrants A reconciliation of the beginning and ending balance of warrants outstanding is as follows: Number of Warrants Outstanding Weighted-Average Exercise Price Subordinate Voting Shares MedMen Corp Redeemable Shares Total Subordinate Voting Shares MedMen Corp Redeemable Shares Total Balance as of June 27, 2020 114,998,915 40,455,731 155,454,646 $ 0.75 $ 0.60 $ 0.71 Issued 229,602,951 147,508,516 377,111,467 $ 0.18 $ 0.28 $ 0.21 Exercised - (40,000,000 ) (40,000,000 ) $ - $ (0.20 ) $ (0.20 ) Cancelled (9,796,509 ) (40,455,731 ) (50,252,240 ) $ (0.50 ) $ (0.44 ) $ (0.45 ) Balance as of March 27, 2021 334,805,358 107,508,516 442,313,874 $ 0.33 $ 0.28 $ 0.32 As of March 27, 2021 and June 27, 2020, warrants outstanding for Subordinate Voting Shares have a weighted-average remaining contractual life of 3.8 years and 4.8 years, respectively. As of March 27, 2021 and June 27, 2020, warrants outstanding for MedMen Corp Redeemable Shares have a weighted-average remaining contractual life of 4.5 years and 2.5 years, respectively. The fair value of warrants exercisable for MedMen Corp Redeemable Shares was determined using the Black-Scholes option-pricing model with the following assumptions on the date of issuance: March 27, June 27 2021 2020 Weighted-Average Risk-Free Annual Interest Rate 0.13 % 2.20 % Weighted-Average Expected Annual Dividend Yield 0 % 0 % Weighted-Average Expected Stock Price Volatility 92.06 % 88.19 % Weighted-Average Expected Life of Warrants 1 year 1 year The fair value of warrants exercisable for the Company’s Subordinate Voting Shares was determined using the Black-Scholes option-pricing model with the following assumptions on the latest modification of December 17, 2020: Weighted-Average Risk-Free Annual Interest Rate 0.16 % Weighted-Average Expected Annual Dividend Yield 0 % Weighted-Average Expected Stock Price Volatility 85.39 % Weighted-Average Expected Life of Warrants 1 year Stock price volatility was estimated by using the historical volatility of the Company’s Subordinate Voting Shares and the average historical volatility of comparable companies from a representative peer group of publicly-traded cannabis companies. The expected life in years represents the period of time that warrants issued are expected to be outstanding. The risk-free rate was based on U.S. Treasury bills with a remaining term equal to the expected life of the warrants. 97,785,140 of warrants are cancelable if the Company meets certain cash flow metrics for nine consecutive months, see “Note 25 – Subsequent Events”

LOSS PER SHARE

LOSS PER SHARE	9 Months Ended
	Mar. 27, 2021
Earnings Per Share [Abstract]
Note 16. LOSS PER SHARE	16. LOSS PER SHARE The following is a reconciliation for the calculation of basic and diluted loss per share for the three and nine months ended March 27, 2021 and March 28, 2020: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. $ (21,328,677 ) $ (19,128,503 ) $ (79,310,611 ) $ (31,648,390 ) Less Deemed Dividend - Down Round Feature of Warrants - - (6,364,183 ) - Net Loss from Continuing Operations Available to Shareholders of MedMen Enterprises, Inc. $ (21,328,677 ) $ (19,128,503 ) $ (85,674,794 ) $ (31,648,390 ) Net Income (Loss) from Discontinued Operations 7,609,983 (5,843,713 ) (6,023,429 ) (58,797,102 ) Total Net Loss $ (13,718,694 ) $ (24,972,216 ) $ (91,698,223 ) $ (90,445,492 ) Weighted-Average Shares Outstanding - Basic and Diluted 541,029,620 315,384,911 482,213,951 65,930,969 Income (Loss) Per Share - Basic and Diluted: From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. $ (0.04 ) $ (0.06 ) $ (0.18 ) $ (0.48 ) From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. $ 0.01 $ (0.02 ) $ (0.01 ) $ (0.89 ) Diluted loss per share is the same as basic loss per share as the issuance of shares on the exercise of convertible debentures, LTIP share units, warrants and share options is anti-dilutive.

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES	9 Months Ended
	Mar. 27, 2021
Research and Development [Abstract]
Note 17. GENERAL AND ADMINISTRATIVE EXPENSES	17. GENERAL AND ADMINISTRATIVE EXPENSES During the three and nine months ended March 27, 2021 and March 28, 2020, general and administrative expenses consisted of the following: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Salaries and Benefits $ 8,787,495 $ 16,809,025 $ 26,904,558 $ 58,876,098 Professional Fees 5,480,969 4,634,854 12,668,101 14,850,558 Rent 7,368,225 7,188,853 22,662,161 21,288,400 Licenses, Fees and Taxes 882,742 3,404,080 5,612,825 11,232,164 Other General and Administrative 6,420,260 10,921,123 21,839,251 44,526,780 Total General and Administrative Expenses $ 28,939,691 $ 42,957,935 $ 89,686,896 $ 150,774,000

OTHER OPERATING EXPENSE

OTHER OPERATING EXPENSE	9 Months Ended
	Mar. 27, 2021
Nonoperating Income (Expense) [Abstract]
Note 18. OTHER OPERATING EXPENSE	18. OTHER OPERATING EXPENSE During the three and nine months ended March 27, 2021 and March 28, 2020, other operating expense (income) consisted of the following: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Loss on Disposals of Assets $ 394,621 $ - $ 779,198 $ 226,335 Restructuring and Reorganization Expense 1,600,721 - 2,781,131 5,564,104 (Gain) Loss on Settlement of Accounts Payable (175,951 ) - 849,737 - Loss (Gain) on Lease Terminations 160,449 - (17,748,368 ) (217,127 ) Gain on Disposal of Assets Held for Sale (255,391 ) - (10,709,999 ) - Other Expense (Income) (165,919 ) 1,848,209 (769,742 ) 1,209,857 Total Other Operating Expense (Income) $ 1,558,530 $ 1,848,209 $ (24,818,043 ) $ 6,783,169

REALIZED AND UNREALIZED LOSS (G

REALIZED AND UNREALIZED LOSS (GAIN) ON INVESTMENTS	9 Months Ended
	Mar. 27, 2021
Restructuring and Related Activities [Abstract]
Note 19. REALIZED AND UNREALIZED LOSS (GAIN) ON INVESTMENTS	19. REALIZED AND UNREALIZED GAIN ON INVESTMENTS During the three and nine months ended March 27, 2021 and March 28, 2020, realized and unrealized gain on investments consisted of the following: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Gain on Changes in Fair Value of Investments - (86,124 ) - (16,600,604 ) Total Realized and Unrealized Gain on Investments $ - $ (86,124 ) $ - $ (16,600,604 )

PROVISION FOR INCOME TAXES AND

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES	9 Months Ended
	Mar. 27, 2021
Income Tax Disclosure [Abstract]
Note 20. PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES	20. PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES The following table summarizes the Company’s income tax expense and effective tax rates for the three and nine months ended March 27, 2021 and March 28, 2020: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Loss from Continuing Operations Before Provision for Income Taxes $ (49,548,705 ) $ (60,651,820 ) $ (103,314,604 ) $ (196,997,174 ) Income Tax Benefit (Expense) 32,207,910 13,836,022 (2,101,121 ) 47,088,266 Effective Tax Rate 65 % 23 % 2 % 24 % Historically, the Company has computed its provision for income taxes under the discrete method which treats the year-to-date period as if it were the annual period and determines the income tax expense or benefit on that basis. For the three and nine months ended March 27, 2021, the Company has calculated its provision for income taxes during its interim reporting periods by applying an estimate of the annual effective tax rate for the full year “ordinary” income or loss for the respective reporting period. Historically, the discrete method was applied due to the reliability of the estimate the annual effective tax rate. The Company believes that, at this time, the use of the estimated annual tax rate is more appropriate under FASB Interpretation No. 18 an interpretation of APB Opinion No. 28 than the discrete method given the Company’s utilization of its forecast. As the Company operates in the legal cannabis industry, the Company is subject to the limits of IRC Section 280E for U.S. federal, Illinois state, Florida state and New York state income tax purposes under which the Company is only allowed to deduct expenses directly related to sales of product. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. However, the State of California does not conform to IRC Section 280E and, accordingly, the Company deducts all operating expenses on its California Franchise Tax Returns. Since IRC Section 280E was not applied in the California Franchise Tax returns, the Company has approximately $76,700,000 of gross California net operating losses which begin expiring in 2038 as of June 27, 2020. The Company has evaluated the realization of its California net operating loss tax attribute and has determined under the more likely than not standard that $2,500,000 will not be realized. The effective tax rate for the three and nine months ended March 27, 2021 varies widely from the three and nine months ended March 28, 2020, respectively, primarily due to the Company reporting increased expenses subject to IRC Section 280E relative to pre-tax book loss. The Company incurred a large amount of expenses that were not deductible due to IRC Section 280E limitations which resulted in income tax expense being incurred while there were pre-tax losses for the nine months ended March 2020. The federal statute of limitations remains open for the 2017 tax year to the present. The state income tax returns generally remain open for the 2016 tax year through the present. Net operating losses arising prior to these years are also open to examination if and when utilized.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Mar. 27, 2021
Commitments and Contingencies Disclosure [Abstract]
Note 21. COMMITMENTS AND CONTINGENCIES	21. COMMITMENTS AND CONTINGENCIES Contingencies The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of these regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management of the Company believes that the Company is in compliance with applicable local and state regulations as of March 27, 2021 and June 27, 2020, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company may be subject to regulatory fines, penalties or restrictions in the future. Claims and Litigation From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of March 27, 2021, there were no pending or threatening lawsuits that could be reasonably assessed to have resulted in a probable loss to the Company in an amount that can be reasonably estimated. As of March 27, 2021, there are also no proceedings in which any of the Company’s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company’s interest. In July 2018, a legal claim was filed against the Company related to alleged misrepresentations in respect of a financing transaction completed in May 2018. The claimant is seeking damages of approximately $2,200,000. The Company believes the likelihood of a loss contingency is remote. As a result, no amount has been set up for potential damages in these financial statements. In late January 2019, the Company’s former Chief Financial Officer (“CFO”) filed a complaint against MM Enterprises in the Superior Court of California, County of Los Angeles, seeking damages for claims relating to his employment. The Company is currently defending against this lawsuit, which seeks damages for wrongful termination, breach of contract, and breach of implied covenant of good faith. The former CFO’s employment agreement provided for the payment of severance in the event of termination without cause. The Company disputes the claims set forth in this lawsuit and believes that the outcome is neither probable nor estimable. As of March 27, 2021, $584,000 has been accrued in the Consolidated Balance Sheet. In March 2020, litigation was filed against the Company related to a purchase agreement for a previous acquisition. The Company is currently defending against this lawsuit, which seeks damages for fraudulent inducement and breach of contract. The Company believes the likelihood of a loss contingency is neither probable nor estimable. As such, no amount has been accrued in these financial statements. In May 2020, litigation was filed against the Company related to a purchase agreement and secured promissory note for a previous acquisition. The Company is currently defending against this lawsuit, which claims for breach of contract, breach of implied covenant of good faith and fair dealing, common law fraud and securities fraud. The plaintiffs are seeking damages for such claims in which the amount is currently not reasonably estimable. Therefore, pursuant to ASC 450, “ Contingencies Note 12 – Notes Payable In September 2020, a legal dispute was filed against the Company related to the separation of a former officer in which the severance issued is currently being disputed. The Company believes the likelihood of loss is remote. As a result, no amount has been set up for potential damages in these financial statements. In February 2020, a legal dispute was filed against the Company and settled in December 2020 for approximately $2,400,000. As of March 27, 2021, the remaining amount has been accrued in the Consolidated Balance Sheet. In January 2021, a cross-complaint was filed against the Company related a lien foreclosure alleging breach of contract, quantum merit and implied indemnity. The Company is actively defending the legal matter which the claimant is seeking damages of approximately $11,000,000. The litigation is at an early stage and thus the likelihood of a loss contingency is remote. As such, no amount has been accrued in these financial statements.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Mar. 27, 2021
Related Party Transactions [Abstract]
Note 22. RELATED PARTY TRANSACTIONS	22. RELATED PARTY TRANSACTIONS All related party balances due to the Company as of March 27, 2021 and June 27, 2020 did not have any formal contractual agreements regarding payment terms or interest. As of February 2020 and May 2020, Mr. Adam Bierman and Mr. Andrew Modlin, respectively, no longer held board or management positions and therefore as of March 27, 2021, they are not considered related parties under ASC 850, “Related Party Disclosures” Pursuant to the Side Letter executed on July 2, 2020 in conjunction with the Fourth Amendment of the Convertible Facility with GGP, Wicklow Capital and GGP have the right to approve director nominees submitted by the Company. The ability to approve the nominees to the Company’s Board of Directors meets the definition of control under ASC 850 and accordingly, Wicklow Capital is a related party of the Company. As of March 27, 2021, the Company determined GGP to be a related party as a result of GGP having significant influence over the Company. See “Note 13 – Senior Secured Convertible Credit Facility” In March 2020, the Company entered into a restructuring plan and retained interim management and advisory firm, Sierra Constellation Partners (“SCP”). As part of the engagement, Tom Lynch was appointed as Interim Chief Executive Officer and Chief Restructuring Officer, and Tim Bossidy was appointed as Interim Chief Operating Officer. Mr. Lynch is a Partner and Senior Managing Director at SCP. Mr. Bossidy is a Director at SCP. In December 2020, Mr. Lynch was elected as Chairman of the Board and Reece Fulgham, a Managing Director at SCP, was appointed as Interim Chief Financial Officer. During the nine months ended March 27, 2021, the Company had paid $2,172,709 in fees to SCP for interim management and restructuring support. During the nine months ended March 27, 2021, Mr. Lynch and Mr. Bossidy each received 124,868 stock options. The Company’s Board of Directors each receive quarterly fees of $200,000 of which one-third is paid in cash and two-thirds is paid in Class B Subordinate Voting Shares. The Class B Subordinate Voting Shares is recorded as a restricted stock unit until settled.

SEGMENTED INFORMATION

SEGMENTED INFORMATION	9 Months Ended
	Mar. 27, 2021
Segmented Information
Note 23. SEGMENTED INFORMATION	23. SEGMENTED INFORMATION The Company currently operates in one segment, the production and sale of cannabis products, which is how the Company’s Chief Operating Decision Maker manages the business and makes operating decisions. The Company’s cultivation operations are not considered significant to the overall operations of the Company. Intercompany sales and transactions are eliminated in consolidation.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended
	Mar. 27, 2021
Discontinued Operations and Disposal Groups [Abstract]
Note 24. DISCONTINUED OPERATIONS	24. DISCONTINUED OPERATIONS During the fiscal year ended June 27, 2020, the Company contemplated the divesture of non-core assets and management entered into a plan to sell its operations in the state of Arizona. Consequently, assets and liabilities allocable to the operations within the state of Arizona were classified as a discontinued operation. The assets associated with the Arizona component have been measured at the lower of their carrying amount or FVLCTS. Revenue and expenses, gains or losses relating to the discontinuation of Arizona operations have been eliminated from profit or loss from the Company’s continuing operations and are shown as a single line item in the unaudited interim Condensed Consolidated Statements of Operations. During the fiscal year ended June 27, 2020, the Company began separate negotiations to sell its operations in the state of Arizona, including the related management entities. In October 2020, Kannaboost Technology Inc. and CSI Solutions LLC (collectively referred to as “Level Up”) was sold at auction for a total sales price of $25,150,000, of which the Company has not received the proceeds as of March 27, 2021. Refer to “ Note 21 - Commitments and Contingencies Note 21 – Commitments and Contingencies On January 29, 2018, the Company acquired all membership interests and assets in Project Compassion NY, LLC (“Project Compassion”) as a part of the formation of MM Enterprises USA through a joint venture. Through Project Compassion, the Company has one cultivation and production facility in Utica, New York, and operates four dispensaries in the state of New York that are located in Buffalo, Lake Success, Salina and Manhattan (collectively, “MedMen NY, Inc.”). During the three months ended March 27, 2021, the Company contemplated the divesture of non-core assets and management entered into a plan to sell MedMen NY, Inc. On February 25, 2021, the Company entered into a definitive investment agreement to sell a controlling interest in MedMen NY, Inc. equity of approximately 86.7% with the option to purchase the remaining equity of approximately 13.3% that the Company will retain in MedMen NY, Inc. following the sale for a total sales price of up to $73,000,000. In conjunction with the investment agreement, MedMen NY, Inc. will engage the services of the purchaser pursuant to a management agreement until regulatory approval has been obtained. The aggregate sales price consists of a cash purchase price of $35,000,000, subject to adjustments and a senior secured promissory note of $28,000,000 which shall be assigned to Hankey Capital in partial satisfaction of the outstanding debt, and within five business days after the first sale by MedMen NY, Inc. of adult-use cannabis products at one or more of its retail store locations, additional shares of MedMen NY, Inc. will be purchased for $10,000,000 in cash. The proceeds in cash will be used to repay a portion of the Hankey Capital notes payable due by the Company. Accordingly, interest expense and amortization of debt discounts and loan origination fees related to the Senior Secured Term Loan Facility totalling $4,797,506 and $2,308,388, was allocated to discontinued operations for the three months ended March 27, 2021 and 2020, respectively and $13,329,130 and $7,507,064 for the nine months ended March 27, 2021 and 2020, respectively. Refer to “Note 12 - Notes Payable” Consequently, assets and liabilities allocable to the operations within the state of New York were classified as a discontinued operation. Revenue and expenses, gains or losses relating to the discontinuation of New York operations have been eliminated from profit or loss from the Company’s continuing operations and are shown as a single line item in the unaudited interim Condensed Consolidated Statements of Operations. The assets associated with the New York component have been measured at the lower of the carrying amount or FVLCTS. The Company will continue to operate the remaining Arizona and New York operations until the ultimate sale of the components. The operating results of the discontinued operations are summarized as follows: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Revenue $ 7,387,484 $ 5,865,570 $ 15,768,813 $ 18,856,242 Cost of Goods Sold 4,621,955 4,746,321 9,788,393 14,051,806 Gross Profit 2,765,529 1,119,249 5,980,420 4,804,436 Expenses: General and Administrative 3,215,889 4,471,200 9,415,436 14,853,915 Sales and Marketing 21,756 2,986 52,857 45,991 Depreciation and Amortization 1,003,276 518,691 2,528,380 2,932,558 Gain on Disposal of Assets (13,375,430 ) - (13,375,430 ) - Impairment Expense - - - 46,702,659 Total Expenses (9,134,509 ) 4,992,877 (1,378,757 ) 64,535,123 Operating Income (Loss) from Discontinued Operations 11,900,038 (3,873,628 ) 7,359,177 (59,730,687 ) Other Expense (Income): Interest Expense 2,629,476 1,985,129 7,549,165 4,066,905 Interest Income (1,545 ) - (1,545 ) - Amortization of Debt Discount and Loan Origination Fees 2,197,946 323,916 5,834,043 3,444,098 Other (Income) Expense (177,006 ) (584 ) (174,341 ) 77,494 Total Other Expense 4,648,871 2,308,461 13,207,322 7,588,497 Income (Loss) on Discontinued Operations Before Provision for Income Taxes 7,251,167 (6,182,089 ) (5,848,145 ) (67,319,184 ) Provision for Income Tax Benefit (Expense) 358,816 338,376 (175,284 ) 8,522,082 Income (Loss) on Discontinued Operations $ 7,609,983 $ (5,843,713 ) $ (6,023,429 ) $ (58,797,102 ) The carrying amounts of assets and liabilities in the disposal group are summarized as follows: March 27, June 27, 2021 2020 Carrying Amounts of the Assets Included in Discontinued Operations: Cash and Cash Equivalents $ 1,115,295 $ 1,198,390 Restricted Cash 5,280 8,844 Accounts Receivable 744,830 283,730 Prepaid Expenses 371,185 172,403 Inventory 6,252,896 6,985,120 Other Current Assets - 64,600 TOTAL CURRENT ASSETS (1) Property and Equipment, Net 15,344,556 15,213,580 Operating Lease Right-of-Use Assets 24,428,302 26,349,789 Intangible Assets, Net 14,255,791 18,936,173 Goodwill 960,691 960,692 Other Assets 525,646 1,688,316 TOTAL NON-CURRENT ASSETS (1) TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 64,004,472 $ 71,861,637 Carrying Amounts of the Liabilities Included in Discontinued Operations: Accounts Payable and Accrued Liabilities $ 4,898,172 $ 6,231,931 Income Taxes Payable 1,273,275 775,714 Other Current Liabilities 326,567 22,747 Current Portion of Operating Lease Liabilities 2,425,234 1,824,862 TOTAL CURRENT LIABILITIES (1) Operating Lease Liabilities, Net of Current Portion 25,540,209 25,417,774 Finance Lease Liabilities, Net of Current Portion 349,312 - Deferred Tax Liabilities 9,710,451 14,663,497 TOTAL NON-CURRENT LIABILITIES (1) TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 44,523,220 $ 48,936,525 (1) The assets and liabilities of the remaining Arizona disposal group and MedMen NY, Inc. classified as held for sale are classified as current on the unaudited interim Condensed Consolidated Balance Sheets as of March 27, 2021 because it is probable that the sale will occur and proceeds will be collected within one year. The assets and liabilities of Level Up classified as held for sale are classified as current in the amounts of $21,181,051 and $15,060,302, respectively, on the audited Consolidated Balance Sheets as of June 27, 2020. The assets and liabilities of MedMen NY, Inc. classified as held for sale are classified as current and noncurrent in the amounts of $4,440,127and $46,228,551, respectively, on the audited Consolidated Balance Sheets as of June 27, 2020. The liabilities of MedMen NY, Inc. classified as held for sale are classified as current and noncurrent in the amounts of $2,915,276 and $30,960,947, respectively, on the audited Consolidated Balance Sheets as of June 27, 2020.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Mar. 27, 2021
Subsequent Events [Abstract]
Note 25. SUBSEQUENT EVENTS	25. SUBSEQUENT EVENTS The Company has evaluated subsequent events through May 11, 2021, which is the date these unaudited interim Condensed Consolidated Financial Statements were issued, and has concluded that the following subsequent events have occurred that would require recognition in the unaudited interim Condensed Consolidated Financial Statements or disclosure in the notes to the unaudited interim Condensed Consolidated Financial Statements. Senior Secured Credit Facility On April 21, 2021, the Company cancelled existing warrants issued to Gotham Green Partners pursuant to the Fifth Amendment of the Senior Secured Credit Facility, see “ Note 13 – Senior Secured Credit Facility

RECLASSIFICATIONS

RECLASSIFICATIONS	9 Months Ended
	Mar. 27, 2021
Reclassifications
Note 26. RECLASSIFICATIONS	26. RECLASSIFICATIONS Certain comparative amounts have been reclassified to conform with current period presentation.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Mar. 27, 2021
Accounting Policies [Abstract]
Basis of Preparation	Basis of Preparation The accompanying unaudited interim Condensed Consolidated Financial Statements have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). The unaudited interim Condensed Consolidated Financial Statements include the accounts of MedMen Enterprises, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in entities in which the Company has significant influence, but less than a controlling financial interest, are accounted for using the equity method. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of March 27, 2021 and June 27, 2020, the consolidated results of operations for the three and nine months ended March 27, 2021 and March 28, 2020, and the consolidated statements of cash flows for the nine months ended March 27, 2021 and March 28, 2020 have been included. The accompanying unaudited interim Condensed Consolidated Financial Statements do not include all of the information required for full annual financial statements. Accordingly, certain information, footnotes and disclosures normally included in the annual financial statements, prepared in accordance with GAAP, have been condensed or omitted in accordance with SEC rules and regulations within the instruction to Form 10-Q and Article 10 of Regulation S-X. The financial data presented herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in Item 13 of the registration statement on Form 10 for the fiscal year ended June 27, 2020.
Going Concern	Going Concern As reflected in the unaudited interim Condensed Consolidated Financial Statements, the Company had an accumulated deficit and a negative net working capital (current liabilities greater than current assets) as of March 27, 2021, as well as a net loss and negative cash flow from operating activities for the reporting period then ended. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these unaudited interim Condensed Consolidated Financial Statements. Management believes that substantial doubt of our ability to meet our obligations for the next twelve months from the date these financial statements were first made available has been alleviated due to, but not limited to, (i) capital raised between May 2021 and May 2022, (ii) restructuring plans that have already been put in place to reduce corporate-level expenses, (iii) debt amendments that have been agreed to with lenders and landlords to defer cash interest and rent payments, (iv) rationalization of capital expenditures to correlate to our new store opening strategy, (v) plans to divest non-core assets to raise non-dilutive capital and (vi) enhancements to its digital offering, including direct-to-consumer delivery and curbside pick-up in light of COVID-19. However, management cannot provide any assurances that we will be successful in accomplishing any of our plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase our need to raise additional capital on an immediate basis. The Company will continually monitor its capital requirements based on its capital and operational needs and the economic environment and may raise new capital as necessary. The Company’s ability to continue as a going concern will depend on its ability to raise additional equity or debt in the private or public markets, reducing operating expenses, divesting of certain non-core assets, and achieving cash flow profitability. While the Company has been successful in raising equity and debt to date, there can be no assurances that the Company will be successful in completing a financing in the future. If the Company is unable to raise additional capital whenever necessary, it may be forced to divest additional assets to raise capital and/or pay down its debt, amend its debt agreements, which could potentially have a dilutive effect on the Company’s shareholders, further reduce operating expenses and temporarily pause the opening of new store locations. Furthermore, COVID-19 and the impact the global pandemic has had and will continue to have on the broader retail environment could also have a significant impact on the Company’s financial operations.
COVID-19	COVID-19 The COVID-19 pandemic promoted various recommendations and safety measures from governmental authorities to try and limit the pandemic. The response of governmental authorities is having a significant impact on the private sector and individuals, including unprecedented business, employment and economic disruptions. During the current reporting period, aspects of the Company’s business continue to be affected by the COVID-19 pandemic, with the Company’s offices and retail stores operating within local rules and regulations. While the ultimate severity of the outbreak and its impact on the economic environment is uncertain, the Company is monitoring this closely. In the event that the Company were to experience widespread transmission of the virus at one or more of the Company’s store or other facilities, the Company could suffer reputational harm or other potential liability. Further, the Company’s business operations may be materially and adversely affected if a significant number of the Company’s employees are impacted by the virus.
Emerging Growth Company	Emerging Growth Company The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act under which emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.
Functional Currency	Functional Currency The Company and its subsidiaries’ functional currency, as determined by management, is the United States (“U.S.”) dollar. These unaudited interim Condensed Consolidated Financial Statements are presented in U.S. dollars as this is the primary economic environment of the group. All references to “C$” refer to Canadian dollars.
Significant Accounting Policies	Significant Accounting Policies The significant accounting policies and critical estimates applied by the Company in these unaudited interim Condensed Consolidated Financial Statements are the same as those applied in the Company’s audited Consolidated Financial Statements and accompanying notes included in Item 13 of the registration statement on Form 10 for the fiscal year ended June 27, 2020, unless otherwise disclosed in these accompanying notes to the unaudited interim Condensed Consolidated Financial Statements for the nine months ended March 27, 2021.
Restricted Cash	Restricted Cash Restricted cash balances are those which meet the definition of cash and cash equivalents but are not available for use by the Company. As of March 27, 2021 and June 27, 2020, restricted cash was $730 and $1,029, respectively, which is used to pay for lease costs and costs incurred related to building construction in Reno, Nevada. This account is managed by a contractor and the Company is required to maintain a certain minimum balance.
Down-Round Provisions	Down-Round Features The Company calculates down-round features under Accounting Standards Update (“ASU”) No. 2017-11 (“ASU 2017-11”), “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features”
Allocation of Interest to Discontinued Operations	Allocation of Interest to Discontinued Operations Under ASC 205-20 “ Discontinued Operations Note 24 – Discontinued Operations
Loss per Share	Loss per Share The Company calculates basic loss per share by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting profit or loss attributable to common shareholders and the weighted-average number of common shares outstanding, for the effects of all dilutive potential common shares, which comprise convertible debentures, DSU, restricted stock grants, warrants and stock options issued.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments” In January 2017, the FASB issued ASU No. 2017-04 “Intangibles— Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” In August 2018, the FASB issued ASU 2018-13, “ Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement
Recently Issued Accounting Standards	Recently Issued Accounting Standards In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes (Topic 740)”, In January 2020, the FASB issued ASU 2020-01, “ Investments – Equity Securities (Topic 321) Investments – Equity Method and Joint Ventures (Topic 323) Derivatives and Hedging (Topic 815) In August 2020, the FASB issued ASU 2020-06, “ Debt – Debt with Conversion and Other Options (Subtopic 470-20) Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible instruments and contracts in an Entity’s Own Equity

INVENTORY (Tables)

INVENTORY (Tables)	9 Months Ended
	Mar. 27, 2021
Inventory Disclosure [Abstract]
Schedule of inventories	As of March 27, 2021 and June 27, 2020, inventory consists of the following: March 27, June 27, 2021 2020 Raw Materials $ 965,641 $ 1,790,050 Work-in-Process 4,760,097 6,229,152 Finished Goods 11,321,882 10,957,776 Total Inventory $ 17,047,620 $ 18,976,978

OTHER CURRENT ASSETS (Tables)

OTHER CURRENT ASSETS (Tables)	9 Months Ended
	Mar. 27, 2021
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Other current assets	As of March 27, 2021 and June 27, 2020, other current assets consist of the following: March 27, June 27, 2021 2020 Investments $ 3,036,791 $ 3,786,791 Excise Tax Receivable - 5,254,595 Note Receivable (1) 1,670,038 - Other Current Assets 3,470,374 64,071 Total Other Current Assets $ 8,177,203 $ 9,105,457
Schedule of Investments	As of March 27, 2021 and June 27, 2020, investments included in other current assets consist of the following: The Hacienda Old Pal Other Investments TOTAL Fair Value as of June 27, 2020 $ 750,000 $ 1,970,000 $ 1,066,791 $ 3,786,791 Settlement of Liabilities (750,000 ) - - (750,000 ) Fair Value as of March 27, 2021 $ - $ 1,970,000 $ 1,066,791 $ 3,036,791

ASSETS HELD FOR SALE (Tables)

ASSETS HELD FOR SALE (Tables)	9 Months Ended
	Mar. 27, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of asset held for sale	A reconciliation of the beginning and ending balances of assets held for sale for the nine months ended March 27, 2021 is as follows: PharmaCann Assets (1) Available for Sale Subsidiaries (2) Discontinued Operations (3) TOTAL Balance at Beginning of Period $ 212,400 $ 12,066,428 $ 71,849,729 $ 84,128,557 Transferred In - 6,614,986 - 6,614,987 Gain on the Sale of Assets Held for Sale - 10,709,999 - 10,709,999 Proceeds from Sale - (24,750,298 ) - (24,750,298 ) Ongoing Activity from Discontinued Operations - (4,641,116 ) (7,845,258 ) (12,486,373 ) Balance at End of Period $ 212,400 $ - $ 64,004,471 $ 64,216,871 (1) During the year ended June 27, 2020, PharmaCann LLC, (“PharmaCann”) transferred 100% of the membership interests for MME Evanston Retail, LLC (“Evanston”), PharmaCann Virginia, LLC (“Staunton”), and PC 16280 East Twombly LLC (“Hillcrest”). As of March 27, 2021, the Company has 100% of membership interests in Staunton which holds land and a license for a vertically-integrated facility in Staunton, Virginia. The Staunton land and license were classified as assets held for sale in accordance with ASC 360, “Long-Lived Assets Classified as Held for Sale” (“ASC 360”) and are measured at the lower of its carrying amount or fair value less costs to sell (“FVLCTS”) which was determined as $212,400 and $0, respectively, as of March 27, 2021. (2) Long-lived assets classified as held for sale that do not qualify as discontinued operation and classified as held for sale. Significant classes of assets and liabilities are presented in the notes to the unaudited interim Condensed Consolidated Financial Statements in accordance with ASC 360-10, “Impairment and Disposal of Long-Lived Assets” (“ASC 360-10”). (3) See “Note 24 - Discontinued Operations” for further information.

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Mar. 27, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	As of March 27, 2021 and June 27, 2020, property and equipment consists of the following: March 27, June 27, 2021 2020 Land and Buildings $ 37,421,326 $ 37,400,378 Finance Lease Right-of-Use Assets 9,124,138 26,074,429 Furniture and Fixtures 12,428,701 12,393,369 Leasehold Improvements 59,551,369 56,026,595 Equipment and Software 25,823,935 25,379,767 Construction in Progress 28,866,937 36,833,422 Total Property and Equipment 173,216,406 194,107,960 Less Accumulated Depreciation (39,039,417 ) (30,484,865 ) Property and Equipment, Net $ 134,176,989 $ 163,623,095

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Mar. 27, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of Intangible assets	As of March 27, 2021 and June 27, 2020, intangible assets consist of the following: March 27, June 27, 2021 2020 Dispensary Licenses $ 118,881,616 $ 125,565,281 Customer Relationships 15,927,600 15,927,600 Management Agreement 7,594,937 7,594,937 Capitalized Software 9,343,352 9,255,026 Intellectual Property 6,276,955 8,520,121 Total Intangible Assets 158,024,460 166,862,965 Dispensary Licenses (20,685,860 ) (15,860,670 ) Customer Relationships (14,210,226 ) (6,261,515 ) Management Agreement (715,761 ) (565,972 ) Capitalized Software (4,071,756 ) (2,273,432 ) Intellectual Property (3,006,772 ) (5,496,231 ) Less Accumulated Amortization (42,690,375 ) (30,457,820 ) Intangible Assets, Net $ 115,334,085 $ 136,405,145

OTHER ASSETS (Tables)

OTHER ASSETS (Tables)	9 Months Ended
	Mar. 27, 2021
Other Income and Expenses [Abstract]
Schedule of other assets	As of March 27, 2021 and June 27, 2020, other assets consist of the following: March 27, June 27, 2021 2020 Long-Term Security Deposits for Leases $ 4,817,042 $ 8,177,871 Loans and Other Long-Term Deposits 7,808,326 7,568,738 Other Assets 5,593 53,648 Total Other Assets $ 12,630,961 $ 15,800,257

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILTIES (Tables)	9 Months Ended
	Mar. 27, 2021
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued liabilities	As of March 27, 2021 and June 27, 2020, accounts payable and accrued liabilities consist of the following: March 27, June 27, 2021 2020 Accounts Payable $ 32,203,779 $ 54,916,904 Accrued Liabilities 14,889,269 10,404,629 Other Accrued Liabilities 10,994,206 10,103,628 Total Accounts Payable and Accrued Liabilities $ 58,087,254 $ 75,425,161

OTHER CURRENT LIABILITIES (Tabl

OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Mar. 27, 2021
Retirement Benefits [Abstract]
Schedule of other current liabilities	As of March 27, 2021 and June 27, 2020, other current liabilities consist of the following: March 27, June 27, 2021 2020 Accrued Interest Payable $ 790,906 $ 9,051,650 Contingent Consideration 87,893 8,951,801 Derivatives 5,707,715 546,076 Other Current Liabilities 14,135,611 1,728,854 Total Other Current Liabilities $ 20,722,125 $ 20,278,381
Schedule of fair value of derivative liabilities	A reconciliation of the beginning and ending balance of derivative liabilities and change in fair value of derivative liabilities for the nine months ended March 27, 2021 is as follows: March 27, 2021 Balance at Beginning of Period $ 546,076 Initial Recognition of Derivative Liabilities 7,228,134 Change in Fair Value of Derivative Liabilities (2,066,495 ) Balance at End of Period $ 5,707,715
Schedule of warrants issued related to the financing transactions	The following are the warrants issued related to the financing transactions that were accounted for as derivative liabilities: Number of Warrants September Bought Deal Equity Financing 7,840,909 December Bought Deal Equity Financing 13,640,000 March 2021 Private Placement 50,000,000 (1) (2) 71,480,909 (1) During the three months ended March 27, 2021, the Company issued 50,000,000 warrants for Subordinate Voting Shares with an exercise price of C$0.50 per warrant and an expiration date of March 27, 2024. The exercise price of the warrants was denominated in a price other than the Company’s functional currency. In accordance with ASC 815, a share warrant denominated in a price other than the functional currency of the Company fails to meet the definition of equity. Accordingly, such a contract or instrument would be accounted for as derivative liabilities and measured at fair value with changes in fair value recognized in the unaudited interim Condensed Consolidated Statements of Operations at each period-end. (2) See “Note 14 - Shareholders’ Equity – Private Placement” for further information.
Schedule of assumptions to measure fair value	The fair value of the March 2021 private placement warrants was measured based on Level 3 inputs on the fair value hierarchy using the Black-Scholes Option pricing model using the following variables: Expected Stock Price Volatility 90.01 % Risk-Free Annual Interest Rate 0.06 % Expected Life 1.00 Share Price 0.33 Exercise Price 0.40

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Mar. 27, 2021
Leases [Abstract]
Schedule of lease cost	The below are the details of the lease cost and other disclosures regarding the Company’s leases for the three and nine months ended March 27, 2021 and March 28, 2020: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Finance Lease Cost: Amortization of Finance Lease Right-of-Use Assets $ 438,557 $ 586,376 $ 835,497 $ 3,203,300 Interest on Lease Liabilities 2,077,724 1,635,017 4,061,842 4,617,716 Operating Lease Cost 7,512,753 6,377,596 20,935,916 19,076,003 Total Lease Expenses $ 10,029,034 $ 8,598,989 $ 25,833,255 $ 26,897,019 2021 2020 2021 2020 Gain on Sale and Leaseback Transactions, Net $ - $ - $ - $ (704,207 ) Cash Paid for Amounts Included in the Measurement of Lease Liabilities: Financing Cash Flows from Finance Leases $ - $ 509,844 $ - $ 807,432 Operating Cash Flows from Operating Leases $ 1,712,630 $ 1,625,567 $ 15,611,252 $ 16,892,734 Non-Cash Additions to Right-of-Use Assets and Lease Liabilities: Recognition of Right-of-Use Assets for Finance Leases $ - $ - $ - $ 45,614,041 Recognition of Right-of-Use Assets for Operating Leases $ - $ 8,131,728 $ - $ 144,602,158
Schedule of Future lease payments	Future lease payments under non-cancellable operating leases and finance leases as of March 27, 2021 are as follows: Fiscal Year Ending Operating Leases Finance Leases June 26, 2021 $ 5,504,585 $ 1,302,684 June 25, 2022 22,989,719 5,324,591 June 24, 2023 23,241,907 5,484,327 June 29, 2024 27,249,872 9,860,306 June 28, 2025 21,096,035 6,522,077 Thereafter 102,173,727 1,076,074,995 Total Lease Payments 202,255,845 1,104,568,980 Less Interest (96,771,980 ) (1,075,923,388 ) Present Value of Lease Liability $ 105,483,865 $ 28,645,592

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Mar. 27, 2021
Debt Disclosure [Abstract]
Schedule of notes payable	As of March 27, 2021 and June 27, 2020, notes payable consist of the following: March 27, June 27, 2021 2020 Financing liability incurred on various dates between January 2019 through September 2019 with implied interest rates ranging from 0.7% to 17.0% per annum. $ 83,400,000 $ 83,576,661 Non-revolving, senior secured term notes dated between October 1, 2018 and October 30, 2020, issued to accredited investors, which mature on January 31, 2022, and bear interest at a rate of 15.5% and 18.0% per annum. 104,436,180 77,675,000 Convertible debentures dated between September 16, 2020 and December 17, 2020, issued to accredited investors and qualified institutional buyers, which mature two years from issuance, and bear interest at a rate of 7.5% per annum. 5,000,000 - Promissory notes dated between January 15, 2019 through March 29, 2019, issued for deferred payments on acquisitions, which mature on varying dates from July 31, 2021 to April 1, 2022 and bear interest at rates ranging from 8.0% to 9.0% per annum. 3,762,500 16,173,250 Promissory notes dated November 7, 2018, issued to Lessor for tenant improvements as part of sales and leaseback transactions, which mature on November 7, 2028, bear interest at a rate of 10.0% per annum and require minimum monthly payments of $15,660 and $18,471. 2,233,720 2,339,564 Other 15,418 15,418 Total Notes Payable 198,847,818 179,779,893 Less Unamortized Debt Issuance Costs and Loan Origination Fees (8,832,434 ) (10,781,288 ) Net Amount $ 190,015,384 $ 168,998,605 Less Current Portion of Notes Payable (97,169,640 ) (16,188,668 ) Notes Payable, Net of Current Portion $ 92,845,744 $ 152,809,937
Schedule of reconciliation notes payable	A reconciliation of the beginning and ending balances of notes payable for the nine months ended March 27, 2021 is as follows: Balance at Beginning of Period $ 168,998,605 Cash Additions 15,830,279 Non-Cash Addition - Debt Modification 877,439 Debt Discount Recognized on Modification (977,370 ) Extinguishment of Debt (12,173,250 ) Paid-In-Kind Interest Capitalized 15,178,462 Cash Payments (660,094 ) Equity Component of Debt- New and Amended (5,583,407 ) Cash Paid for Debt Issuance Costs 99,931 Accretion of Debt Discount included in Discontinued Operations 5,834,043 Accretion of Debt Discount 2,590,746 Balance at End of Period $ 190,015,384 Less Current Portion of Notes Payable (97,169,640 ) Notes Payable, Net of Current Portion $ 92,845,744

SENIOR SECURED CONVERTIBLE CR_2

SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Tables)	9 Months Ended
	Mar. 27, 2021
Risks and Uncertainties [Abstract]
Schedule of senior secured convertible credit facility	As of March 27, 2021 and June 27, 2020, senior secured convertible credit facility consists of the following: March 27, June 27, Tranche 2021 2020 Senior secured convertible notes dated April 23, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 1A $ 20,674,403 $ 21,660,583 Senior secured convertible notes dated May 22, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 1B 89,039,556 86,053,316 Senior secured convertible notes dated July 12, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 2 28,953,899 26,570,948 Senior secured convertible notes dated November 27, 2019, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 3 11,211,533 10,288,815 Senior secured convertible notes dated March 27, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. 4 13,609,724 12,500,000 Amendment fee converted to senior secured convertible notes dated October 29, 2019, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 21,165,550 19,423,593 Senior secured convertible notes dated April 24, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. IA-1 2,959,951 2,734,282 Senior secured convertible notes dated September 14, 2020, issued to accredited investors, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. IA-2 5,724,068 - Restatement fee issued in senior secured convertible notes dated March 27, 2020, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 8,513,121 8,199,863 Second restatement fee issued in senior secured convertible notes dated July 2, 2020, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 1,979,156 - Third restatement fee issued in senior secured convertible notes dated January 11, 2021, which mature on April 23, 2022 and bear interest at LIBOR plus 6.0% per annum. - 11,131,939 - Total Drawn on Senior Secured Convertible Credit Facility 214,962,900 187,431,400 Less Unamortized Debt Discount (57,897,490 ) (21,062,937 ) Senior Secured Convertible Credit Facility, Net $ 157,065,410 $ 166,368,463
Schedule of reconciliation senior secured convertible credit facilty	A reconciliation of the beginning and ending balances of senior secured convertible credit facility for the nine months ended March 27, 2021 is as follows: Tranche 1 Tranche 2 Tranche 3 Tranche 4 Incremental Advance - 1 Incremental Advance - 2 3rd Advance Amendment Restatement Fee Notes 2nd Restatement Fee Notes TOTAL Balance as of June 27, 2020 $ 102,833,447 $ 25,352,687 $ 9,680,433 $ 286,691 $ 2,168,540 $ - $ - $ 18,964,600 $ 7,082,065 $ - 166,368,463 Cash Additions - - - - - 5,420,564 10,937,127 - - - 16,357,691 Repayments (8,000,000 ) - - - - - - - - - (8,000,000 ) Principal Reallocation 585,058 (3,276 ) (1,277 ) (404,451 ) (340 ) (589 ) - (2,395 ) (24,084 ) (148,646 ) - Fees Capitalized to Debt Related to - - - - - (468,564 ) (937,127 ) - - - (1,405,691 ) Paid-In-Kind Interest Capitalized 9,396,021 2,386,229 923,996 1,115,478 226,009 303,299 194,812 1,744,352 736,039 127,802 17,154,037 Net Effect on Debt from Extinguishment 4,812,996 962,750 497,175 2,167,870 (453,979 ) - - 455,792 630,758 2,000,000 11,073,362 Equity Component Debt - New (23,562,662 ) (6,147,968 ) (2,480,673 ) (2,839,499 ) (1,296,844 ) (3,239,507 ) (7,694,405 ) (4,337,438 ) (4,551,977 ) - (56,150,973 ) Cash Paid for Debt Issuance Costs - - - - - (175,000 ) (200,000 ) - - - (375,000 ) Amortization of Debt Discounts 5,394,019 1,282,359 531,455 1,057,893 414,622 726,545 565,258 971,013 1,099,158 1,198 12,043,520 Balance as of March 27, 2021 $ 91,458,879 $ 23,832,781 $ 9,151,109 $ 1,383,982 $ 1,058,008 $ 2,566,748 $ 2,865,665 $ 17,795,924 $ 4,971,959 $ 1,980,354 $ 157,065,410

SHAREHOLDERS EQUITY (Tables)

SHAREHOLDERS EQUITY (Tables)	9 Months Ended
	Mar. 27, 2021
MEZZANINE EQUITY:
Schedule of Shares issued and outstanding	A reconciliation of the beginning and ending issued and outstanding shares is as follows: Subordinate Voting Super MM CAN USA MM Enterprises USA Balance as of June 27, 2020 403,907,218 815,295 236,123,851 725,016 Cancellation of Super Voting Shares - (815,295 ) - - Shares Issued for Cash 57,800,000 - - - Shares Issued to Settle Accounts Payable and Liabilities 14,911,047 - - - Shares Issued for Exercise of Warrants - - 27,164,323 - Redemption of MedMen Corp Redeemable Shares 133,969,228 - (133,969,228 ) - Shares Issued for Vested Restricted Stock Units 7,173,256 - - - Shares Issued for Debt Amendment Fees 4,305,148 - - - Stock Grants for Compensation 3,703,730 - - - Balance as of March 27, 2021 625,769,627 - 129,318,946 725,016
Schedule of VIE	As of and for the nine months ended March 27, 2021, the balances of the VIEs before any intercompany eliminations consists of the following: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,197,557 $ - $ 10,310,942 $ 11,508,499 Non-Current Assets 13,045,511 2,925,798 4,980,057 20,951,366 Total Assets $ 14,243,068 $ 2,925,798 $ 15,290,999 $ 32,459,865 Current Liabilities $ 10,836,220 $ 9,032,248 $ 3,083,532 $ 22,952,000 Non-Current Liabilities 7,827,937 2,386,061 7 10,214,005 Total Liabilities $ 18,664,157 $ 11,418,309 $ 3,083,539 $ 33,166,005 Non-Controlling Interest $ (4,421,089 ) $ (8,492,511 ) $ 12,207,460 $ (706,140 ) Revenues $ 6,457,626 $ - $ 9,911,450 $ 16,369,076 Net Income (Loss) Attributable to Non-Controlling Interest $ 1,504,096 $ (2,422,184 ) $ 5,427,833 $ 4,509,745 As of and for the year ended June 27, 2020, the balances of the VIEs consists of the following: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. TOTAL Current Assets $ 1,233,188 $ 811,025 $ 6,639,231 $ 8,683,444 Non-Current Assets 16,867,824 3,259,563 5,032,428 25,159,815 Total Assets $ 18,101,012 $ 4,070,588 $ 11,671,659 $ 33,843,259 Current Liabilities $ 12,831,161 $ 7,481,953 $ 3,745,710 $ 24,058,824 Non-Current Liabilities 11,196,585 2,662,078 1,146,322 15,004,985 Total Liabilities $ 24,027,746 $ 10,144,031 $ 4,892,032 $ 39,063,809 Non-Controlling Interest $ (5,926,734 ) $ (6,073,443 ) $ 6,779,627 $ (5,220,550 ) Revenues $ 10,949,458 $ - $ 13,976,810 $ 24,926,268 Net Income (Loss) Attributable to Non-Controlling Interest $ (6,132,528 ) $ (3,777,079 ) $ 3,143,437 $ (6,766,170 )
Schedule of other non-controlling interest	The net change in the consolidated VIEs and other non-controlling interest are as follows for the nine months ended March 27, 2021: Venice Caregivers Foundation, Inc. LAX Fund II Group, LLC Natures Cure, Inc. Other Non- Controlling Interests TOTAL Balance as of June 27, 2020 $ (5,925,185 ) $ (6,070,327 ) $ 6,779,627 $ (331,561,812 ) $ (336,777,697 ) Net Income (Loss) 1,504,096 (2,422,184 ) 5,427,833 (30,614,859 ) (26,105,114 ) Equity Component on Debt and Debt Modification - - - 4,055,133 4,055,133 Deferred Tax Impact On Conversion Feature - - - (1,210,052 ) (1,210,052 ) Redemption of MedMen Corp Redeemable Shares - - - (75,460,832 ) (75,460,832 ) Balance as of March 27, 2021 $ (4,421,089 ) $ (8,492,511 ) $ 12,207,460 $ (434,792,422 ) $ (435,498,562 )

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Mar. 27, 2021
Share-based Payment Arrangement [Abstract]
Schedule of share-based compensation expense	A summary of share-based compensation expense for the three and nine months ended March 27, 2021 and March 28, 2020 is as follows: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Stock Options $ 305,565 $ (69,571 ) $ 2,851,785 $ 2,584,933 LTIP Units - 179,014 - 1,492,073 Stock Grants for Services, Net (63,189 ) 1,151,366 58,043 3,041,012 Restricted Stock Grants - 916,842 437,386 3,727,485 Total Share-Based Compensation $ 242,376 $ 2,177,651 $ 3,347,214 $ 10,845,503
Schedule of Black-Scholes option-pricing model	For the nine months ended March 27, 2021 and March 28, 2020, the fair value of stock options granted with a fixed exercise price was determined using the Black-Scholes option-pricing model with the following assumptions at the time of grant: Nine Months Ended March 27, March 28, 2021 2020 Weighted-Average Risk-Free Annual Interest Rate 1.05 % 1.70 % Weighted-Average Expected Annual Dividend Yield 0.0 % 0.0 % Weighted-Average Expected Stock Price Volatility 116.5 % 87.9 % Weighted-Average Expected Life in Years 7.50 7.50 Weighted-Average Estimated Forfeiture Rate 40.0 % 40.0 %
Schedule of stock options	A reconciliation of the beginning and ending balance of stock options outstanding is as follows: Number of Stock Options Weighted- Balance as of June 27, 2020 8,618,204 $ 2.78 Granted 7,318,669 Forfeited (1,344,375 ) Balance as of March 27, 2021 14,592,498 $ 1.48 Stock Options Exercisable as of March 27, 2021 12,769,339 $ 1.45
Schedule of LTIP Units and LLC Redeemable Units	A reconciliation of the beginning and ending balances of the LTIP Units and LLC Redeemable Units issued for compensation outstanding is as follows: Weighted LTIP Units LLC Average Issued and Redeemable Grant Date Outstanding Units Fair Value Balance as of June 27, 2020 and March 27, 2021 19,323,878 725,016 $ 0.52
Schedule of Deferred Stock Units	A reconciliation of the beginning and ending balance of DSUs outstanding is as follows: Issued and Outstanding Weighted- Balance as of June 27, 2020 1,283,567 $ 0.38 Settled (1,283,567 ) $ (0.38 ) Balance as of March 27, 2021 - $ -
Schedule of Restricted Stock Grants	A reconciliation of the beginning and ending balance of restricted stock grants outstanding is as follows: Issued and Outstanding Vested Weighted- Balance as of June 27, 2020 7,159,164 192,459 $ 0.68 Granted (1) 28,210,512 - $ 0.17 Forfeiture of Restricted Stock (2) (4,240,013 ) - $ (0.20 ) Redemption of Vested Stock (8,107,249 ) (8,107,249 ) $ (0.26 ) Vesting of Restricted Stock - 8,533,485 $ 0.35 Balance as of March 27, 2021 23,022,414 618,695 $ 0.28 (1) Issued on December 11, 2020 to certain officers and employees of the Company and vest 37.5%, 12.5%, 37.5%, 12.5% on the 1st, 2nd, 3rd and 4th anniversary, respectively. (2) 4,240,013 of the restricted stock grants were forfeited upon the resignation of certain employees prior to their vesting.
Schedule of Warrants	A reconciliation of the beginning and ending balance of warrants outstanding is as follows: Number of Warrants Outstanding Weighted-Average Exercise Price Subordinate Voting Shares MedMen Corp Redeemable Shares Total Subordinate Voting Shares MedMen Corp Redeemable Shares Total Balance as of June 27, 2020 114,998,915 40,455,731 155,454,646 $ 0.75 $ 0.60 $ 0.71 Issued 229,602,951 147,508,516 377,111,467 $ 0.18 $ 0.28 $ 0.21 Exercised - (40,000,000 ) (40,000,000 ) $ - $ (0.20 ) $ (0.20 ) Cancelled (9,796,509 ) (40,455,731 ) (50,252,240 ) $ (0.50 ) $ (0.44 ) $ (0.45 ) Balance as of March 27, 2021 334,805,358 107,508,516 442,313,874 $ 0.33 $ 0.28 $ 0.32
Schedule of fair value of warrants	The fair value of warrants exercisable for MedMen Corp Redeemable Shares was determined using the Black-Scholes option-pricing model with the following assumptions on the date of issuance: March 27, June 27 2021 2020 Weighted-Average Risk-Free Annual Interest Rate 0.13 % 2.20 % Weighted-Average Expected Annual Dividend Yield 0 % 0 % Weighted-Average Expected Stock Price Volatility 92.06 % 88.19 % Weighted-Average Expected Life of Warrants 1 year 1 year The fair value of warrants exercisable for the Company’s Subordinate Voting Shares was determined using the Black-Scholes option-pricing model with the following assumptions on the latest modification of December 17, 2020: Weighted-Average Risk-Free Annual Interest Rate 0.16 % Weighted-Average Expected Annual Dividend Yield 0 % Weighted-Average Expected Stock Price Volatility 0.81 Weighted-Average Expected Life of Warrants 1 year

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	9 Months Ended
	Mar. 27, 2021
Earnings Per Share [Abstract]
Schedule of basic and diluted loss per share	The following is a reconciliation for the calculation of basic and diluted loss per share for the three and nine months ended March 27, 2021 and March 28, 2020: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc. $ (21,328,677 ) $ (19,128,503 ) $ (79,310,611 ) $ (31,648,390 ) Less Deemed Dividend - Down Round Feature of Warrants - - (6,364,183 ) - Net Loss from Continuing Operations Available to Shareholders of MedMen Enterprises, Inc. $ (21,328,677 ) $ (19,128,503 ) $ (85,674,794 ) $ (31,648,390 ) Net Income (Loss) from Discontinued Operations 7,609,983 (5,843,713 ) (6,023,429 ) (58,797,102 ) Total Net Loss $ (13,718,694 ) $ (24,972,216 ) $ (91,698,223 ) $ (90,445,492 ) Weighted-Average Shares Outstanding - Basic and Diluted 541,029,620 315,384,911 482,213,951 65,930,969 Income (Loss) Per Share - Basic and Diluted: From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc. $ (0.04 ) $ (0.06 ) $ (0.18 ) $ (0.48 ) From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc. $ 0.01 $ (0.02 ) $ (0.01 ) $ (0.89 )

GENERAL AND ADMINISTRATIVE EX_2

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	9 Months Ended
	Mar. 27, 2021
Research and Development [Abstract]
Schedule of general and administrative expenses	During the three and nine months ended March 27, 2021 and March 28, 2020, general and administrative expenses consisted of the following: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Salaries and Benefits $ 8,787,495 $ 16,809,025 $ 26,904,558 $ 58,876,098 Professional Fees 5,480,969 4,634,854 12,668,101 14,850,558 Rent 7,368,225 7,188,853 22,662,161 21,288,400 Licenses, Fees and Taxes 882,742 3,404,080 5,612,825 11,232,164 Other General and Administrative 6,420,260 10,921,123 21,839,251 44,526,780 Total General and Administrative Expenses $ 28,939,691 $ 42,957,935 $ 89,686,896 $ 150,774,000

OTHER OPERATING EXPENSE (Tables

OTHER OPERATING EXPENSE (Tables)	9 Months Ended
	Mar. 27, 2021
Nonoperating Income (Expense) [Abstract]
Schedule of other operating expenses	During the three and nine months ended March 27, 2021 and March 28, 2020, other operating expense (income) consisted of the following: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Loss on Disposals of Assets $ 394,621 $ - $ 779,198 $ 226,335 Restructuring and Reorganization Expense 1,600,721 - 2,781,131 5,564,104 (Gain) Loss on Settlement of Accounts Payable (175,951 ) - 849,737 - Loss (Gain) on Lease Terminations 160,449 - (17,748,368 ) (217,127 ) Gain on Disposal of Assets Held for Sale (255,391 ) - (10,709,999 ) - Other Expense (Income) (165,919 ) 1,848,209 (769,742 ) 1,209,857 Total Other Operating Expense (Income) $ 1,558,530 $ 1,848,209 $ (24,818,043 ) $ 6,783,169

REALIZED AND UNREALIZED LOSS _2

REALIZED AND UNREALIZED LOSS (GAIN) ON INVESTMENTS (Tables)	9 Months Ended
	Mar. 27, 2021
Restructuring and Related Activities [Abstract]
Schedule of realized and unrealized loss (gain) on investments and assets held for sale	During the three and nine months ended March 27, 2021 and March 28, 2020, realized and unrealized gain on investments consisted of the following: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Gain on Changes in Fair Value of Investments - (86,124 ) - (16,600,604 ) Total Realized and Unrealized Gain on Investments $ - $ (86,124 ) $ - $ (16,600,604 )

PROVISION FOR INCOME TAXES AN_2

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Tables)	9 Months Ended
	Mar. 27, 2021
Income Tax Disclosure [Abstract]
Schedule of income tax expense and effective tax rates	The following table summarizes the Company’s income tax expense and effective tax rates for the three and nine months ended March 27, 2021 and March 28, 2020: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Loss from Continuing Operations Before Provision for Income Taxes $ (49,548,705 ) $ (60,651,820 ) $ (103,314,604 ) $ (196,997,174 ) Income Tax Benefit (Expense) 32,207,910 13,836,022 (2,101,121 ) 47,088,266 Effective Tax Rate 65 % 23 % 2 % 24 %

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended
	Mar. 27, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of net operating loss of discontinued operation	The Company will continue to operate the remaining Arizona and New York operations until the ultimate sale of the components. The operating results of the discontinued operations are summarized as follows: Three Months Ended Nine Months Ended March 27, March 28, March 27, March 28, 2021 2020 2021 2020 Revenue $ 7,387,484 $ 5,865,570 $ 15,768,813 $ 18,856,242 Cost of Goods Sold 4,621,955 4,746,321 9,788,393 14,051,806 Gross Profit 2,765,529 1,119,249 5,980,420 4,804,436 Expenses: General and Administrative 3,215,889 4,471,200 9,415,436 14,853,915 Sales and Marketing 21,756 2,986 52,857 45,991 Depreciation and Amortization 1,003,276 518,691 2,528,380 2,932,558 Gain on Disposal of Assets (13,375,430 ) - (13,375,430 ) - Impairment Expense - - - 46,702,659 Total Expenses (9,134,509 ) 4,992,877 (1,378,757 ) 64,535,123 Operating Income (Loss) from Discontinued Operations 11,900,038 (3,873,628 ) 7,359,177 (59,730,687 ) Other Expense (Income): Interest Expense 2,629,476 1,985,129 7,549,165 4,066,905 Interest Income (1,545 ) - (1,545 ) - Amortization of Debt Discount and Loan Origination Fees 2,197,946 323,916 5,834,043 3,444,098 Other (Income) Expense (177,006 ) (584 ) (174,341 ) 77,494 Total Other Expense 4,648,871 2,308,461 13,207,322 7,588,497 Income (Loss) on Discontinued Operations Before Provision for Income Taxes 7,251,167 (6,182,089 ) (5,848,145 ) (67,319,184 ) Provision for Income Tax Benefit (Expense) 358,816 338,376 (175,284 ) 8,522,082 Income (Loss) on Discontinued Operations $ 7,609,983 $ (5,843,713 ) $ (6,023,429 ) $ (58,797,102 )
Schedule of assets included in discontinued operation	The carrying amounts of assets and liabilities in the disposal group are summarized as follows: March 27, June 27, 2021 2020 Carrying Amounts of the Assets Included in Discontinued Operations: Cash and Cash Equivalents $ 1,115,295 $ 1,198,390 Restricted Cash 5,280 8,844 Accounts Receivable 744,830 283,730 Prepaid Expenses 371,185 172,403 Inventory 6,252,896 6,985,120 Other Current Assets - 64,600 TOTAL CURRENT ASSETS (1) Property and Equipment, Net 15,344,556 15,213,580 Operating Lease Right-of-Use Assets 24,428,302 26,349,789 Intangible Assets, Net 14,255,791 18,936,173 Goodwill 960,691 960,692 Other Assets 525,646 1,688,316 TOTAL NON-CURRENT ASSETS (1) TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 64,004,472 $ 71,861,637 Carrying Amounts of the Liabilities Included in Discontinued Operations: Accounts Payable and Accrued Liabilities $ 4,898,172 $ 6,231,931 Income Taxes Payable 1,273,275 775,714 Other Current Liabilities 326,567 22,747 Current Portion of Operating Lease Liabilities 2,425,234 1,824,862 TOTAL CURRENT LIABILITIES (1) Operating Lease Liabilities, Net of Current Portion 25,540,209 25,417,774 Finance Lease Liabilities, Net of Current Portion 349,312 - Deferred Tax Liabilities 9,710,451 14,663,497 TOTAL NON-CURRENT LIABILITIES (1) TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE $ 44,523,220 $ 48,936,525 (1) The assets and liabilities of the remaining Arizona disposal group and MedMen NY, Inc. classified as held for sale are classified as current on the unaudited interim Condensed Consolidated Balance Sheets as of March 27, 2021 because it is probable that the sale will occur and proceeds will be collected within one year. The assets and liabilities of Level Up classified as held for sale are classified as current in the amounts of $21,181,051 and $15,060,302, respectively, on the audited Consolidated Balance Sheets as of June 27, 2020. The assets and liabilities of MedMen NY, Inc. classified as held for sale are classified as current and noncurrent in the amounts of $4,440,127and $46,228,551, respectively, on the audited Consolidated Balance Sheets as of June 27, 2020. The liabilities of MedMen NY, Inc. classified as held for sale are classified as current and noncurrent in the amounts of $2,915,276 and $30,960,947, respectively, on the audited Consolidated Balance Sheets as of June 27, 2020.

NATURE OF OPERATIONS (Details N

NATURE OF OPERATIONS (Details Narrative)	Jan. 24, 2018shares
MM Enterprises USA [Member]
Shares received	217,184,382

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Accounting Policies [Abstract]
Restricted cash	$ 730	$ 1,029

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Inventory Disclosure [Abstract]
Raw Materials	$ 965,641	$ 1,790,050
Work-in-Process	4,760,097	6,229,152
Finished Goods	11,321,882	10,957,776
Total Inventory	$ 17,047,620	$ 18,976,978

INVENTORIES (Details Narrative)

INVENTORIES (Details Narrative)	3 Months Ended
	Mar. 27, 2021USD ($)
Inventory Disclosure [Abstract]
Write down inventory	$ 1,714,000

OTHER CURRENT ASSETS (Details)

OTHER CURRENT ASSETS (Details) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Other Current Assets	$ 8,177,203	$ 9,105,457
Other Current Assets [Member]
Investments	3,036,791	3,786,791
Excise Tax Receivable		5,254,595
Notes Receivable	1,670,038
Other Current Assets	3,470,374	64,071
Total Other Current Assets	$ 8,177,203	$ 9,105,457

OTHER CURRENT ASSETS (Details 1

OTHER CURRENT ASSETS (Details 1)	9 Months Ended
	Mar. 27, 2021USD ($)
Fair value beginning balance	$ 3,786,791
Settlement of Liabilities	(750,000)
Fair value evening balance	3,036,791
The Hacienda Company LLC [Member]
Fair value beginning balance	750,000
Settlement of Liabilities	(750,000)
Fair value evening balance
Old Pal [Member]
Fair value beginning balance	1,970,000
Settlement of Liabilities
Fair value evening balance	1,970,000
Other Investments [Member]
Fair value beginning balance	1,066,791
Settlement of Liabilities
Fair value evening balance	$ 1,066,791

OTHER CURRENT ASSETS (Details N

OTHER CURRENT ASSETS (Details Narrative)	Mar. 27, 2021USD ($)
The Hacienda Company LLC [Member]
Settlement of outstanding balances	$ 750,000
Old Pal [Member]
Fair Value of investment	$ 1,970,000

ASSETS HELD FOR SALE (Details)

ASSETS HELD FOR SALE (Details)	9 Months Ended
	Mar. 27, 2021USD ($)
Balance at Beginning of Period	$ 37,900,006
Balance at End of Period	64,216,871
Available For Sale Subsidiaries [Member]
Balance at Beginning of Period	12,066,428
Transferred In	6,614,986
Gain on the Sale of Assets Held for Sale	10,709,999
Proceeds from Sale	(24,750,298)
Ongoing Activity from Discontinued Operations	(4,641,116)
Balance at End of Period
Discontinued Operations [Member]
Balance at Beginning of Period	71,849,729
Transferred In
Gain on the Sale of Assets Held for Sale
Proceeds from Sale
Ongoing Activity from Discontinued Operations	(7,845,258)
Balance at End of Period	64,004,471
Total [Member]
Balance at Beginning of Period	84,128,557
Transferred In	6,614,987
Gain on the Sale of Assets Held for Sale	10,709,999
Proceeds from Sale	(24,750,298)
Ongoing Activity from Discontinued Operations	(12,486,373)
Balance at End of Period	64,216,871
Pharma Cann Assets [Member]
Balance at Beginning of Period	212,400
Transferred In
Gain on the Sale of Assets Held for Sale
Proceeds from Sale
Ongoing Activity from Discontinued Operations
Balance at End of Period	$ 212,400

ASSETS HELD FOR SALE (Details N

ASSETS HELD FOR SALE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Nov. 17, 2020	Jun. 26, 2020	Mar. 27, 2021	Mar. 28, 2020	Dec. 26, 2020	Jun. 27, 2020
Carrying Amount of the Assets Included in Assets Held for Sale
Equity consideration			$ 18,885,912	$ 50,193,938
MME Evanston Retail, LLC [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Membership interests					100.00%
Staunton [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Membership interests						100.00%
Purchase agreement [Member] | Third party [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Purchase consideration for ownership interest			3,750,000
Purchase consideration, cash consideration			3,500,000
Equity consideration			250,000
Gain on sale of membership interests			$ 255,391
Separate Agreements [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Membership interests			100.00%
Gain on sale of membership interests			$ 332,747
Aggregate sale price		$ 1,500,000
Agreement Description			Non-binding term sheet for the retail location located in Seaside, California for an aggregate sales price of $1,500,000 wherein $750,000 is to be paid upon the date of close in addition to $750,000 paid in equal monthly installments over twelve months through a promissory note. The transaction closed in October 2020 and the Company transferred all outstanding membership interests in PHSL, LLC. Upon deconsolidation, the Company will not have any continuing involvement with the former subsidiary. The Company recognized a loss upon sale of membership interests of $332,747 for the difference between the aggregate consideration and the book value of the assets as of the disposition date, less direct costs to sell
July 1, 2020 [Member]
Carrying Amount of the Assets Included in Assets Held for Sale
Gain on sale of membership interests			$ 12,415,479
Consideration			20,000,000
Cash received			10,000,000
Additional Cash	$ 8,000,000
Secured promissory note			$ 2,000,000

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Investments, Debt and Equity Securities [Abstract]
Land and Buildings	$ 37,421,326	$ 37,400,378
Finance Lease Right-of-Use Assets	9,124,138	26,074,429
Furnitures and Fixtures	12,428,701	12,393,369
Leasehold improvements	59,551,369	56,026,595
Equipment and Software	25,823,935	25,379,767
Construction in Progress	28,866,937	36,833,422
Total Property and Equipment	173,216,406	194,107,960
Less Accumulated Depreciation	(39,039,417)	(30,484,865)
Property and Equipment, Net	$ 134,176,989	$ 163,623,095

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Investments, Debt and Equity Securities [Abstract]
Depreciation Expense	$ 3,540,369	$ 3,680,139	$ 12,116,847	$ 13,331,921
Cost of Good Sold	42,452	536,729	383,618	1,640,176
Right of use assets	438,557	586,376	835,497	3,203,300
Borrowing costs		$ 2,106,988		$ 4,415,716
Average capitalization rate		13.70%		15.10%
Labor related costs	52,351	$ 137,558	559,515	$ 913,627
Construction in progress	$ 6,992	$ 19,475	$ 155,378	$ 192,130

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Total Intangible Assets	$ 158,024,460	$ 166,862,965
Less Accumulated Amortization	(42,690,375)	(30,457,820)
Intangible Assets, Net	115,334,085	136,405,145
Dispensary License [Member]
Total Intangible Assets	118,881,616	125,565,281
Less Accumulated Amortization	(20,685,860)	(15,860,670)
Capitalized Software [Member]
Total Intangible Assets	9,343,352	9,255,026
Less Accumulated Amortization	(4,071,756)	(2,273,432)
Customer Relationship [Member]
Total Intangible Assets	15,927,600	15,927,600
Less Accumulated Amortization	(14,210,226)	(6,261,515)
Intellectual Property [Member]
Total Intangible Assets	6,276,955	8,520,121
Less Accumulated Amortization	(3,006,772)	(5,496,231)
Management Agreement [Member]
Total Intangible Assets	7,594,937	7,594,937
Less Accumulated Amortization	$ (715,761)	$ (565,972)

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Investments, Debt and Equity Securities [Abstract]
Amortization expense	$ 4,452,573	$ 4,333,212	$ 13,104,322	$ 10,660,164
Impairment on intellectual property asset	1,573,563
Share based compensation	$ 24,832	$ 41,293	$ 62,951	$ 313,535

OTHER ASSETS (Details)

OTHER ASSETS (Details) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Other Current Assets	$ 8,177,203	$ 9,105,457
Other Assets [Member]
Long-Term Security Diposits for Leases	4,817,042	8,177,871
Loans and Other Long-Term Diposits	7,808,326	7,568,738
Other Current Assets	5,593	53,648
Total Other Assets	$ 12,630,961	$ 15,800,257

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Total Accounts Payable and Accrued Liabilities	$ 20,722,125	$ 20,278,381
Accounts Payable and Accrued Liabilities [Member]
Accounts Payable	32,203,779	54,916,904
Accrued Liabilities	14,889,269	10,404,629
Other Accrued Liabilities	10,994,206	10,103,628
Total Accounts Payable and Accrued Liabilities	$ 58,087,254	$ 75,425,161

OTHER CURRENT LIABILITIES (Deta

OTHER CURRENT LIABILITIES (Details) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Total Accounts Payable and Accrued Liabilities	$ 20,722,125	$ 20,278,381
Total Other Current Liabilities	3,790,561	4,215,533
Other Current Liabilities and Other Non-Current Liabilities [Member]
Accrued Interest Payable	790,906	9,051,650
Contingent Consideration	87,893	8,951,801
Derivatives	5,707,715	546,076
Total Accounts Payable and Accrued Liabilities	14,135,611	1,728,854
Total Other Current Liabilities	$ 20,722,125	$ 20,278,381

OTHER CURRENT LIABILITIES (De_2

OTHER CURRENT LIABILITIES (Details 1)	9 Months Ended
	Mar. 27, 2021shares
Number of Warrants	71,480,909
Equity Financing [Member]
Number of Warrants	7,840,909
Equity Financing [Member]
Number of Warrants	13,640,000
Private Placement [Member]
Number of Warrants	50,000,000

OTHER CURRENT LIABILITIES (De_3

OTHER CURRENT LIABILITIES (Details 2) - USD ($)	9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Payables and Accruals [Abstract]
Balance at Beginning of Period	$ 546,076
Initial Recognition of Derivative Liabilities	7,228,134
Change in Fair Value of Derivative Liabilities	(2,066,495)	$ (8,041,429)
Balance at End of Period	$ 5,707,715

OTHER CURRENT LIABILITIES (De_4

OTHER CURRENT LIABILITIES (Details 3)	9 Months Ended
	Mar. 27, 2021$ / shares
Payables and Accruals [Abstract]
Expected Stock Price Volatility	90.01%
Risk-Free Annual Interest Rate	6.00%
Expected Life	1 year
Share Price	$ 0.33
Exercise Price	$ 0.4

LEASES (Details)

LEASES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Finance Lease Cost
Amortization of Finance Lease Right-of-Use Assets	$ 438,557	$ 586,376	$ 835,497	$ 3,203,300
Interest on Lease Liabilities	2,077,724	1,635,017	4,061,842	4,617,716
Operating Lease Cost	7,512,753	6,377,596	20,935,916	19,076,003
Total Lease Expenses	10,029,034	8,598,989	25,833,255	26,897,019
Gain on Sale and Leaseback Transactions, Net				(704,207)
Cash Paid for Amount Includedin the Measurementof Lease Liabilities:
Financing Cash Flow from Financing Leases		509,844		807,432
Operating Cash Flow from Operating Leases	1,712,630	1,625,567	15,611,252	16,892,734
Non Cash Additional to Right-of-Use Assets and Lease Liabilities
Recognition of Right-of-Use Assets for Finance Leases				45,614,041
Recognition of Right-of-Use Assets for Operating Leases		$ 8,131,728		$ 144,602,158

LEASES (Details 1)

LEASES (Details 1)	Mar. 27, 2021USD ($)
Operating Leases
June 26, 2021	$ 5,504,585
June 25, 2022	22,989,719
June 24, 2023	23,241,907
June 29, 2024	27,249,872
June 28, 2025	21,096,035
Thereafter	102,173,727
Total lease payment	202,255,845
Less: Interest	(96,771,980)
Present Value of Lease Liabilities	105,483,865
Finance Leases
June 26, 2021	1,302,684
June 25, 2022	5,324,591
June 24, 2023	5,484,327
June 29, 2024	9,860,306
June 28, 2025	6,522,077
Thereafter	1,076,074,995
Total lease payment	1,104,568,980
Less: Interest	(1,075,923,388)
Present Value of Lease Liabilities	$ 28,645,592

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	9 Months Ended
	Mar. 27, 2021	Oct. 30, 2020	Sep. 16, 2020	Jul. 02, 2020
Accrued interest				8.60%
Finance lease discount rate	17.77%
Finance Weighted-average remaining lease term	48 years
Operating lease discount rate	10.25%
Operating Weighted-average remaining lease term	5 years
Warrants issued		77,052,790	30,000,000
REIT [Member]
Gain on lease modification	$ 16,274,615
Warrants issued				3,500,000
Exercisable price				$ 0.34

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Finance liabilities	$ 204,770	$ 1,644,044
Total notes Payables	92,845,744	152,809,937
Convertible Notes Payable [Member]
Finance liabilities	83,400,000	83,576,661
Non-revolving, senior secured term notes	104,436,180	77,675,000
Convertible debentures	5,000,000
Promissory notes	3,762,500	16,173,250
Promissory notes	2,233,720	2,339,564
Other	15,418	15,418
Total notes Payables	198,847,818	179,779,893
Less. Unamortization Debt Issuance Cost an Loan Origination Fess	(8,832,434)	(10,781,288)
Net Amount	190,015,384	168,998,605
Less Current Portion of Notes Payable	(97,169,640)	(16,188,668)
Notes Payables, net of Current Portion	$ 92,845,744	$ 152,809,937

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - Notes Payable [Member]	9 Months Ended
	Mar. 27, 2021USD ($)
Balance at beginning of period Notes payables	$ 168,998,605
Cash additions	15,830,279
Non-cash Addition-Debt modification	877,439
Debt discount Recognized on modifacation	(977,370)
Extinguishment of Debt	(12,173,250)
Paid in kind interest Capitalized	15,178,462
Cash payments	(660,094)
Equity Component of Debt- New and Amended	(5,583,407)
Cash paid for debt issuance costs	99,931
Accretion of Debt Discount included in Discontinued Operations	5,834,043
Accreation of debt discount	2,590,746
Balance at ending of period Notes payables	190,015,384
Less Current portion of notes payables	(97,169,640)
Notes payable, Net of Current portion	$ 92,845,744

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended
	Dec. 17, 2020	Nov. 20, 2020	Oct. 30, 2020	Sep. 16, 2020	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020	Sep. 29, 2020	Jul. 02, 2020	Jun. 27, 2020
Amendment fee							$ 834,000
Warrants issued			77,052,790	30,000,000
Principal term Loan			$ 7,705,279	$ 3,000,000					$ 3,000,000	$ 77,675,000
Increase in additional paid in capital				$ 405,480	$ 892,713,747		$ 892,713,747				$ 791,172,613
Warrants adjusted price				$ 0.17
Warrants exercise price			$ 0.20	$ 0.20			$ 0.60
Warrants exercisable, issued							20,227,863
Warrants exercisable, per share							$ 0.34
Existing warrants, cancelled							20,227,863
Maturity Date			Sep. 14, 2025	Sep. 16, 2025			Dec. 31, 2022
Fair value of warrant issued							$ 799,949
Additional debt discount				$ 542,986			906,436
Loss on extinguishment					6,420,526	$ 11,570,696	17,493,887	$ 43,800,931
Gain on disposal of assets					394,621		779,198	$ 226,335
Tranche 2 [Member]
Warrants exercise price				$ 0.17
Warrants exercisable, issued				3,777,475
Debt conversion price									$ 0.15
Unsecured convertible debt									$ 1,000,000
Tranche 5 [Member]
Warrants issued			77,052,790	5,700,000
Increase in funds under facility				$ 12,000,000
Description				The additional amounts are funded through incremental term loans at an interest rate of 18.0% per annum wherein 12.0% shall be paid in cash monthly in arrears and 6.0% shall accrue monthly as payment-in-kind. In connection with each incremental draw under the amended Facility, the Company shall issue warrants equal to 200% of the incremental term loan amount, divided by the greater of (a) $0.20 per share and (b) 115% multiplied
Rate of Interest				18.00%
Tranche 4 [Member]
Warrants exercise price	$ 0.18
Warrants exercisable, issued	3,597,100
Debt conversion price	$ 0.15
Unsecured convertible debt	$ 1,000,000
Tranche 3 [Member]
Warrants exercise price		$ 0.17
Warrants exercisable, issued		3,592,425
Debt conversion price		$ 0.15
Unsecured convertible debt		$ 1,000,000
Acquisition Promissory Note [Member]
Gain on disposal of assets							13,375,430
Amendment to Promissory Note [Member]
Principal amount					$ 3,500,000		$ 3,500,000
Maturity Date							Apr. 1, 2022
Interest rate							9.00%
Loss on extinguishment							$ 2,410,504
Convertible Debt [Member]
Warrants exercise price				$ 0.21
Warrants exercisable, issued				3,293,413
Proceeds convertible debenture				$ 10,000,000
Interest rate				7.50%
Additional tranches amount				$ 1,000,000
Maximum tranche amount				$ 10,000,000
Interest paid				7.50%
Conversion of debt Amount				$ 1,000,000
Conversion price				$ 0.17
Voting share, greater than				$ 0.25
Hankey Capital [Member]
Principal term Loan										$ 77,675,000
Description							Shall accrue monthly to the outstanding principal as payment-in-kind effective March 1, 2020 through July 2, 2021. Thereafter until maturity on January 31, 2022, one-half of the interest (7.75% per annum) shall be payable monthly in cash and one-half of the interest (7.75% per annum) shall be paid-in-kind.
Rate of Interest										15.50%
Loss on extinguishment							$ 4,010,022

SENIOR SECURED CONVERTIBLE CR_3

SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details ) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Total Drawn On Senior Secured Convertible Credit Facility	$ 214,962,900	$ 187,431,400
Less Unamortize Debt Discount	(57,897,490)	(21,062,937)
Senior Secured Convertible Credit Facility Net	157,065,410	166,368,463
Secured Convertible Note [Member]
Total Drawn On Senior Secured Convertible Credit Facility	20,674,403	21,660,583
Secured Convertible Note 1 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	89,039,556	86,053,316
Secured Convertible Note 2 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	28,953,899	26,570,948
Secured Convertible Note 3 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	11,211,533	10,288,815
Secured Convertible Note 4 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	13,609,724	12,500,000
Secured Convertible Note 5 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	21,165,550	19,423,593
Secured Convertible Note 6 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	2,959,951	2,734,282
Secured Convertible Note 7 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	5,724,068	0
Secured Convertible Note 8 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	8,513,121	8,199,863
Secured Convertible Note 9 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	1,979,156	0
Secured Convertible Note 9 [Member]
Total Drawn On Senior Secured Convertible Credit Facility	$ 11,131,939	$ 0

SENIOR SECURED CONVERTIBLE CR_4

SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details 1)	9 Months Ended
	Mar. 27, 2021USD ($)
Senior Secured Convertible, Total [Member]
Balance at beginning of period Notes payables	$ 166,368,463
Cash additions	16,357,691
Repayments	(8,000,000)
Principal Reallocation	0
Fees Capitalized to Debt Related to Debt Modifications	(1,405,691)
Paid-In-Kind Interest Capitalized	17,154,037
Net Effect on Debt from Extinguishment	11,073,362
Net Effect on Equity Component of New and Amended Debt	(56,150,973)
Cash Paid for Debt Issuance Costs	(375,000)
Amortization of Debt Discounts	12,043,520
Balance at ending of period Notes payables	157,065,410
Tranche 1 [Member]
Balance at beginning of period Notes payables	102,833,447
Cash additions	0
Repayments	(8,000,000)
Principal Reallocation	585,058
Fees Capitalized to Debt Related to Debt Modifications	0
Paid-In-Kind Interest Capitalized	9,396,021
Net Effect on Debt from Extinguishment	4,812,996
Net Effect on Equity Component of New and Amended Debt	(23,562,662)
Cash Paid for Debt Issuance Costs	0
Amortization of Debt Discounts	5,394,019
Balance at ending of period Notes payables	91,458,879
Tranche 2 [Member]
Balance at beginning of period Notes payables	25,352,687
Cash additions	0
Repayments	0
Principal Reallocation	(3,276)
Fees Capitalized to Debt Related to Debt Modifications	0
Paid-In-Kind Interest Capitalized	2,386,229
Net Effect on Debt from Extinguishment	962,750
Net Effect on Equity Component of New and Amended Debt	(6,147,968)
Cash Paid for Debt Issuance Costs	0
Amortization of Debt Discounts	1,282,359
Balance at ending of period Notes payables	23,832,781
Tranche 3 [Member]
Balance at beginning of period Notes payables	9,680,433
Cash additions	0
Repayments	0
Principal Reallocation	(1,277)
Fees Capitalized to Debt Related to Debt Modifications	0
Paid-In-Kind Interest Capitalized	923,996
Net Effect on Debt from Extinguishment	497,175
Net Effect on Equity Component of New and Amended Debt	(2,480,673)
Cash Paid for Debt Issuance Costs	0
Amortization of Debt Discounts	531,455
Balance at ending of period Notes payables	9,151,109
Tranche 4 [Member]
Balance at beginning of period Notes payables	286,691
Cash additions	0
Repayments	0
Principal Reallocation	(404,451)
Fees Capitalized to Debt Related to Debt Modifications	0
Paid-In-Kind Interest Capitalized	1,115,478
Net Effect on Debt from Extinguishment	2,167,870
Net Effect on Equity Component of New and Amended Debt	(2,839,499)
Cash Paid for Debt Issuance Costs	0
Amortization of Debt Discounts	1,057,893
Balance at ending of period Notes payables	1,383,982
Incremental Advance - 1 [Member]
Balance at beginning of period Notes payables	2,168,540
Cash additions	0
Repayments	0
Principal Reallocation	(340)
Fees Capitalized to Debt Related to Debt Modifications	0
Paid-In-Kind Interest Capitalized	226,009
Net Effect on Debt from Extinguishment	(453,979)
Net Effect on Equity Component of New and Amended Debt	(1,296,844)
Cash Paid for Debt Issuance Costs	0
Amortization of Debt Discounts	414,622
Balance at ending of period Notes payables	1,058,008
Incremental Advance - 2 [Member]
Balance at beginning of period Notes payables	0
Cash additions	5,420,564
Repayments	0
Principal Reallocation	(589)
Fees Capitalized to Debt Related to Debt Modifications	(468,564)
Paid-In-Kind Interest Capitalized	303,299
Net Effect on Debt from Extinguishment	0
Net Effect on Equity Component of New and Amended Debt	(3,239,507)
Cash Paid for Debt Issuance Costs	(175,000)
Amortization of Debt Discounts	726,545
Balance at ending of period Notes payables	2,566,748
3rd Advance [Member]
Balance at beginning of period Notes payables	0
Cash additions	10,937,127
Repayments	0
Principal Reallocation	0
Fees Capitalized to Debt Related to Debt Modifications	(937,127)
Paid-In-Kind Interest Capitalized	194,812
Net Effect on Debt from Extinguishment	0
Net Effect on Equity Component of New and Amended Debt	(7,694,405)
Cash Paid for Debt Issuance Costs	(200,000)
Amortization of Debt Discounts	565,258
Balance at ending of period Notes payables	2,865,665
Amendment Fee Notes [Member]
Balance at beginning of period Notes payables	18,964,600
Cash additions	0
Repayments	0
Principal Reallocation	(2,395)
Fees Capitalized to Debt Related to Debt Modifications	0
Paid-In-Kind Interest Capitalized	1,744,352
Net Effect on Debt from Extinguishment	455,792
Net Effect on Equity Component of New and Amended Debt	(4,337,438)
Cash Paid for Debt Issuance Costs	0
Amortization of Debt Discounts	971,013
Balance at ending of period Notes payables	17,795,924
Restatement Fee Notes [Member]
Balance at beginning of period Notes payables	7,082,065
Cash additions	0
Repayments	0
Principal Reallocation	(24,084)
Fees Capitalized to Debt Related to Debt Modifications	0
Paid-In-Kind Interest Capitalized	736,039
Net Effect on Debt from Extinguishment	630,758
Net Effect on Equity Component of New and Amended Debt	(4,551,977)
Cash Paid for Debt Issuance Costs	0
Amortization of Debt Discounts	1,099,158
Balance at ending of period Notes payables	4,971,959
2nd Restatement Fee Notes [Member]
Balance at beginning of period Notes payables	0
Cash additions	0
Repayments	0
Principal Reallocation	(148,646)
Fees Capitalized to Debt Related to Debt Modifications	0
Paid-In-Kind Interest Capitalized	127,802
Net Effect on Debt from Extinguishment	2,000,000
Net Effect on Equity Component of New and Amended Debt	0
Cash Paid for Debt Issuance Costs	0
Amortization of Debt Discounts	1,198
Balance at ending of period Notes payables	$ 1,980,354

SENIOR SECURED CONVERTIBLE CR_5

SENIOR SECURED CONVERTIBLE CREDIT FACILITY (Details Narrative ) - USD ($)	Sep. 14, 2020	Sep. 16, 2020	Mar. 27, 2021	Sep. 26, 2020	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
conversion price	$ 0.20	$ 0.17
Convertible notes	$ 468,564					$ 32,744,770
Secured convertible notes	$ 5,000,000					6,723,954
Loss on Extinguishment of Debt			$ 6,420,526		$ 11,570,696	17,493,887	$ 43,800,931
Amendment fee						834,000
November 1, 2020 [Member]
Amount of borrowing under convertible facility			8,000,000			8,000,000
Loss on Extinguishment of Debt			$ 943,706
GGP [Member]
Exercise price	$ 0.20
conversion price	$ 0.200
Secured convertible notes	$ 5,000,000
Description of Note	The conversion price for 5.0% of the existing Notes outstanding prior to Tranche 4 and Incremental Advance (including paid-in-kind interest accrued on such Notes), being 5.0% of an aggregate principal amount of $170,729,923, was amended to $0.20 per share.
Warrant Issued	25,000,000
Cancelled Shares	1,080,255
Warrants replaced	16,875,001
GGP [Member] | On July 2, 2020[Member]
conversion price				$ 0.28
Secured convertible notes				$ 5,000,000
Description of Amendments Penalty				the Convertible Facility with a 5% prepayment penalty until 2nd anniversary of the Fourth Amendment and 3% prepayment penalty thereafter.
Amendment fee				$ 2,000,000
Description Of Amendments				the conversion price for 52% of the tranches 1 through 3 and the first amendment fee notes outstanding under the Convertible Facility were amended to $0.34 per share
GGP [Member]
Loss on Extinguishment of Debt						$ (10,129,655)

SHAREHOLDERS EQUITY (Details)

SHAREHOLDERS EQUITY (Details)	9 Months Ended
	Mar. 27, 2021shares
Subordinate Voting Shares [Member]
Shares issued and outstanding, Beginning of the period	403,907,218
Cancellation of Super Voting Shares
Shares Issued for Cash	57,800,000
Shares Issued to Settle Accounts Payable and Liabilities	14,911,047
Shares Issued for Exercise of Warrants
Redemption of MedMen Corp Redemable Shares	133,969,228
Shares Issued for Vested Restricted Stock Units	7,173,256
Shares Issued for Debt Amendment Fees	4,305,148
Stock Grant for Compensation	3,703,730
Shares issued and outstanding, End of the period	625,769,627
Super Voting Shares [Member]
Shares issued and outstanding, Beginning of the period	815,295
Cancellation of Super Voting Shares	(815,295)
Shares Issued for Cash
Shares Issued to Settle Accounts Payable and Liabilities
Shares Issued for Exercise of Warrants
Redemption of MedMen Corp Redemable Shares
Shares Issued for Vested Restricted Stock Units
Shares Issued for Debt Amendment Fees
Stock Grant for Compensation
Shares issued and outstanding, End of the period
MM CAN USA Class B Redeemable Units[Member]
Shares issued and outstanding, Beginning of the period	236,123,851
Cancellation of Super Voting Shares
Shares Issued for Cash
Shares Issued to Settle Accounts Payable and Liabilities
Shares Issued for Exercise of Warrants	27,164,323
Redemption of MedMen Corp Redemable Shares	(133,969,228)
Shares Issued for Vested Restricted Stock Units
Shares Issued for Debt Amendment Fees
Stock Grant for Compensation
Shares issued and outstanding, End of the period	129,318,946
MM Enterprises USA Common Units[Member]
Shares issued and outstanding, Beginning of the period	725,016
Cancellation of Super Voting Shares
Shares Issued for Cash
Shares Issued to Settle Accounts Payable and Liabilities
Shares Issued for Exercise of Warrants
Redemption of MedMen Corp Redemable Shares
Shares Issued for Vested Restricted Stock Units
Shares Issued for Debt Amendment Fees
Stock Grant for Compensation
Shares issued and outstanding, End of the period	725,016

SHAREHOLDERS EQUITY (Details 1)

SHAREHOLDERS EQUITY (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 27, 2021	Jun. 27, 2020
VIEs, Total [Member]
Current Assets	$ 11,508,499	$ 8,683,444
Non-Current Assets	20,951,366	25,159,815
Total Assets	32,459,865	33,843,259
Current Liabilities	22,952,000	24,058,824
Non-Current Liabilities	10,214,005	15,004,985
Total Liabilities	33,166,005	39,063,809
Non-Controlling Interest	(706,140)	(5,220,550)
Revenues	16,369,076	24,926,268
Net (Loss) Income Attributable to Non-Controlling Interest	4,509,745	(6,766,170)
Venice Caregivers Foundation, Inc. [Member]
Current Assets	1,197,557	1,233,188
Non-Current Assets	13,045,511	16,867,824
Total Assets	14,243,068	18,101,012
Current Liabilities	10,836,220	12,831,161
Non-Current Liabilities	7,827,937	11,196,585
Total Liabilities	18,664,157	24,027,746
Non-Controlling Interest	(4,421,089)	(5,926,734)
Revenues	6,457,626	10,949,458
Net (Loss) Income Attributable to Non-Controlling Interest	1,504,096	(6,132,528)
LAX Fund 2 Group, L.L.C [Member]
Current Assets		811,025
Non-Current Assets	2,925,798	3,259,563
Total Assets	2,925,798	4,070,588
Current Liabilities	9,032,248	7,481,953
Non-Current Liabilities	2,386,061	2,662,078
Total Liabilities	11,418,309	10,144,031
Non-Controlling Interest	(8,492,511)	(6,073,443)
Revenues
Net (Loss) Income Attributable to Non-Controlling Interest	(2,422,184)	(3,777,079)
Natures Cure, Inc. [Member]
Current Assets	10,310,942	6,639,231
Non-Current Assets	4,980,057	5,032,428
Total Assets	15,290,999	11,671,659
Current Liabilities	3,083,532	3,745,710
Non-Current Liabilities	7	1,146,322
Total Liabilities	3,083,539	4,892,032
Non-Controlling Interest	12,207,460	6,779,627
Revenues	9,911,450	13,976,810
Net (Loss) Income Attributable to Non-Controlling Interest	$ 5,427,833	$ 3,143,437

SHAREHOLDERS EQUITY (Details 2)

SHAREHOLDERS EQUITY (Details 2)	9 Months Ended
	Mar. 27, 2021USD ($)shares
Venice Caregivers Foundation, Inc. [Member]
Shares issued and Redeemable, Beginning of the period	$ (5,925,185)
Net Income (Loss)	1,504,096
Equity Component on Debt and Debt Modification
Deferred Tax Impact on Conversion Feature
Redemption of MedMen Crop Redeemable Shares | shares
Shares issued and Redemption, End of the period	$ (4,421,089)
LAX Fund 2 Group, L.L.C [Member]
Shares issued and Redeemable, Beginning of the period	(6,070,327)
Net Income (Loss)	(2,422,184)
Equity Component on Debt and Debt Modification
Deferred Tax Impact on Conversion Feature
Redemption of MedMen Crop Redeemable Shares | shares
Shares issued and Redemption, End of the period	$ (8,492,511)
Natures Cure, Inc. [Member]
Shares issued and Redeemable, Beginning of the period	6,779,627
Net Income (Loss)	5,427,833
Equity Component on Debt and Debt Modification
Deferred Tax Impact on Conversion Feature
Redemption of MedMen Crop Redeemable Shares | shares
Shares issued and Redemption, End of the period	$ 12,207,460
Other Non Controlling Interests [Member]
Shares issued and Redeemable, Beginning of the period	(331,561,812)
Net Income (Loss)	(30,614,859)
Equity Component on Debt and Debt Modification	4,055,133
Deferred Tax Impact on Conversion Feature	$ (1,210,052)
Redemption of MedMen Crop Redeemable Shares | shares	(75,460,832)
Shares issued and Redemption, End of the period	$ (434,792,422)
Total [Member]
Shares issued and Redeemable, Beginning of the period	(336,777,697)
Net Income (Loss)	(26,105,114)
Equity Component on Debt and Debt Modification	4,055,133
Deferred Tax Impact on Conversion Feature	$ (1,210,052)
Redemption of MedMen Crop Redeemable Shares | shares	(75,460,832)
Shares issued and Redemption, End of the period	$ (435,498,562)

SHAREHOLDERS EQUITY (Details Na

SHAREHOLDERS EQUITY (Details Narrative)	Mar. 27, 2021	Jun. 27, 2020
MM CAN USA Class B Redeemable Units[Member]
Non-controlling interest, shares issued	17.13%
MM Enterprises USA Common Units [Member]
Non-controlling interest, shares issued	0.10%	0.11%
MM CAN USA [Member]
Non-controlling interest, shares issued		36.89%

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Total Share-Based Compensation	$ 242,376	$ 2,177,651	$ 4,164,466	$ 10,845,503
Equity Option [Member]
Total Share-Based Compensation	305,565	(69,571)	2,851,785	2,584,933
LTIP Units [Member]
Total Share-Based Compensation		179,014		1,492,073
Stock Grants [Member]
Total Share-Based Compensation	(63,189)	1,151,366	58,043	3,041,012
Restricted Stock Grants [Member]
Total Share-Based Compensation		$ 916,842	$ 437,386	$ 3,727,485

SHARE-BASED COMPENSATION (Det_2

SHARE-BASED COMPENSATION (Details 1)	9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020
Investments, Debt and Equity Securities [Abstract]
Weighted Average Risk Free Annual Interest Rate	1.05%	1.70%
Weighted Average Expected Annual Dividend Yield	0.00%	0.00%
Weighted Average Expected Stock Price Volatility	116.50%	87.90%
Weighted-Average Expected Life in Years	7 years 6 months	7 years 6 months
Weighted-Average Estimated Forfeiture Rate	40.00%	40.00%

SHARE-BASED COMPENSATION (Det_3

SHARE-BASED COMPENSATION (Details 2)	9 Months Ended
	Mar. 27, 2021$ / sharesshares
Investments, Debt and Equity Securities [Abstract]
Number of Stock Options, Beginning Balance | shares	8,618,204
Number of Stock Options, Granted | shares	7,318,669
Number of Stock Options, Forfeited | shares	(1,344,375)
Number of Stock Options, Ending Balance | shares	14,592,498
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.78
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 1.48
Number of Stock Option Exerciable | shares	12,769,339
Weighted Average Exerciable Price | $ / shares	$ 1.45

SHARE-BASED COMPENSATION (Det_4

SHARE-BASED COMPENSATION (Details 3)	Mar. 27, 2021$ / sharesshares
Investments, Debt and Equity Securities [Abstract]
LTIP Issued And Outstanding	19,323,878
LIC Redeemable Units	725,016
Weighted Average grant date fair Value | $ / shares	$ 0.52

SHARE-BASED COMPENSATION (Det_5

SHARE-BASED COMPENSATION (Details 4)	9 Months Ended
	Mar. 27, 2021$ / sharesshares
Investments, Debt and Equity Securities [Abstract]
Issued And Outstanding Beginning Balance | shares	1,283,567
Issued And Outstanding, Settled | shares	(1,283,567)
Issued And Outstanding, Ending Balance | shares	0
Weighted Average Fair Value, Begning Balance | $ / shares	$ 0.38
Weighted Average fair Value, Settled | $ / shares	(0.38)
Weighted Average Fair Value, Ending Balance | $ / shares	$ 0

SHARE-BASED COMPENSATION (Det_6

SHARE-BASED COMPENSATION (Details 5)	9 Months Ended
	Mar. 27, 2021$ / sharesshares
Investments, Debt and Equity Securities [Abstract]
Issued And Outstanding, Beginning Balance	7,159,164
Issued And Outstanding, Granted	28,210,512
Issued And Outstanding, Forfeiture of Restricted Stock	(4,240,013)
Issued And Outstanding, Redemption of Vested Stock	(8,107,249)
Issued And Outstanding, Vesting of Restricted Stock
Issued And Outstanding, Ending Balance	23,022,414
Vested, Beginning Balance	192,459
Vested, Granted
Vested, Forfeiture of Restricted Stock
Vested, Redemption of Vested Stock	(8,107,249)
Vested, Vesting of Restricted Stock	8,533,485
Vested, Ending Balance	618,695
Weighted Average fair Value Beginning Balance | $ / shares	$ 0.68
Weighted Average fair Value, Granted | $ / shares	0.17
Weighted Average fair Value, Forfeiture of Restricted Stock | $ / shares	(0.20)
Weighted Average fair Value, Redemption of Vested Stock | $ / shares	(0.26)
WeightedAverage Fair Value, Vesting of Restricted Stock | $ / shares	0.35
WeightedAverage Fair Value, Ending Balance | $ / shares	$ 0.28

SHARE-BASED COMPENSATION (Det_7

SHARE-BASED COMPENSATION (Details 6) - Warrant [Member]	9 Months Ended
	Mar. 27, 2021$ / sharesshares
Beginning Balance | shares	155,454,646
Issued | shares	377,111,467
Exercised | shares	(40,000,000)
Cancelled | shares	(50,252,240)
Ending Balance | shares	442,313,874
Weighted Average Exercise Price, Beginning balance | $ / shares	$ 0.71
Weighted Average Exercise Price, issued | $ / shares	0.21
Weighted Average Exercise Price, exercised | $ / shares	(0.20)
Weighted Average Exercise Price, Cancelled | $ / shares	(0.45)
Weighted Average Exercise Price, Ending | $ / shares	$ 0.32
[Subordinate Voting Shares [Member]]
Beginning Balance | shares	114,998,915
Issued | shares	229,602,951
Exercised | shares
Cancelled | shares	(9,796,509)
Ending Balance | shares	334,805,358
Weighted Average Exercise Price, Beginning balance | $ / shares	$ 0.75
Weighted Average Exercise Price, issued | $ / shares	0.18
Weighted Average Exercise Price, exercised | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares	(0.50)
Weighted Average Exercise Price, Ending | $ / shares	$ 0.33
MedMax Corp Redeemable Shares [Member]
Beginning Balance | shares	40,455,731
Issued | shares	147,508,516
Exercised | shares	(40,000,000)
Cancelled | shares	(40,455,731)
Ending Balance | shares	107,508,516
Weighted Average Exercise Price, Beginning balance | $ / shares	$ 0.6
Weighted Average Exercise Price, issued | $ / shares	0.28
Weighted Average Exercise Price, exercised | $ / shares	(0.20)
Weighted Average Exercise Price, Cancelled | $ / shares	(0.44)
Weighted Average Exercise Price, Ending | $ / shares	$ 0.28

SHARE-BASED COMPENSATION (Det_8

SHARE-BASED COMPENSATION (Details 7)	9 Months Ended	12 Months Ended
	Mar. 27, 2021	Jun. 27, 2020
Investments, Debt and Equity Securities [Abstract]
Weighted Average Risk Free Annual Interest Rate	0.13%	2.20%
Weighted Average Expected Annual Dividend Yield	0.00%	0.00%
Weighted Average Expected Stock Price Volatility	92.06%	88.19%
Weighted Average Expected Life OF Warrants	1 year	1 year

SHARE-BASED COMPENSATION (Det_9

SHARE-BASED COMPENSATION (Details 8)	1 Months Ended
	Dec. 17, 2020
Investments, Debt and Equity Securities [Abstract]
Weighted Average Risk Free Annual Interest Rate	0.16%
Weighted Average Expected Annual Dividend Yield	0.00%
Weighted Average Expected Stock Price Volatility	85.39%
Weighted Average Expected Life of Warrants	1 year

SHARE-BASED COMPENSATION (De_10

SHARE-BASED COMPENSATION (Details Narrative) - USD ($)	2 Months Ended	9 Months Ended	12 Months Ended
	Aug. 30, 2020	Mar. 27, 2021	Jun. 27, 2020
Exercise price Maturity date		10 years
Restricted Voting Shares		28,210,512
Cancelable Warrants		97,785,140
DSU [Member]
Deferred stock units issued and outstanding		0	1,283,567
Voting Shares Service Amount	$ 250,000
Warrant One [Member] | Subordinate Voting Shares [Member]
Warrants outstanding contractual life		4 years 9 months 18 days	3 years 9 months 18 days
Warrant One [Member] | MedMax Corp Redeemable Shares [Member]
Warrants outstanding contractual life		4 years 6 months	2 years 6 months

LOSS PER SHARE (Details)

LOSS PER SHARE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Earnings Per Share [Abstract]
Net Loss from Continuing Operations Attributable to Shareholders of MedMen Enterprises, Inc.	$ (21,328,677)	$ (19,128,503)	$ (79,310,611)	$ (31,648,390)
Less: Deemed Dividend - Down Round Feature of Warrants			(6,364,183)
Net Loss from Continuing Operations Available to Shareholders of MedMen Enterprises, Inc.	(21,328,677)	(19,128,503)	(85,674,794)	(31,648,390)
Net Income (Loss) from Discontinued Operations	7,609,983	(5,843,713)	(6,023,429)	(58,797,102)
Total Net Loss	$ (13,718,694)	$ (24,972,216)	$ (91,698,223)	$ (90,445,492)
Weighted-Average Shares Outstanding - Basic and Diluted	541,029,620	315,384,911	482,213,951	65,930,969
Income (Loss) Per Share - Basic and Diluted:
From Continuing Operations Attributable to Shareholders of MedMen Enterprises Inc.	$ (0.04)	$ (0.06)	$ (0.18)	$ (0.48)
From Discontinued Operations Attributable to Shareholders of MedMen Enterprises Inc.	$ 0.01	$ (0.02)	$ (0.01)	$ (0.89)

GENERAL AND ADMINISTRATIVE EX_3

GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Unusual or Infrequent Items, or Both [Abstract]
Professional Fees	$ 8,787,495	$ 16,809,025	$ 26,904,558	$ 58,876,098
Salaries and Benefits	5,480,969	4,634,854	12,668,101	14,850,558
Rent	7,368,225	7,188,853	22,662,161	21,288,400
Licenses, Fees and Taxes	882,742	3,404,080	5,612,825	11,232,164
Other General and Administrative Expenses	6,420,260	10,921,123	21,839,251	44,526,780
Total General and Administrative Expenses	$ 28,939,691	$ 42,957,935	$ 89,686,896	$ 150,774,000

OTHER OPERATING EXPENSE (Detail

OTHER OPERATING EXPENSE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Research and Development [Abstract]
Loss on Disposals of Assets	$ 394,621		$ 779,198	$ 226,335
Restructuring and Reorganization Expense	1,600,721		2,781,131	5,564,104
(Gain) Loss on Settlement of Accounts Payable	(175,951)		849,737
Loss (Gain) on Lease Terminations	160,449		(17,748,368)	(217,127)
Gain on Disposal of Assets Held for Sale	(255,391)		(10,709,999)
Other Expense (Income)	(165,919)	1,848,209	(769,742)	1,209,857
Total Other Operating Expense (Income)	$ 1,558,530	$ 1,848,209	$ (24,818,043)	$ 6,783,169

REALIZED AND UNREALIZED LOSS _3

REALIZED AND UNREALIZED LOSS (GAIN) ON INVESTMENTS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Restructuring and Related Activities [Abstract]
Gain on Changes in Fair Value of Investments		$ (86,124)		$ (16,600,604)
Tota Realized and Unrealized Loss (Gain) on Investments and Assets Held for Sale		$ (86,124)		$ (16,600,604)

PROVISION FOR INCOME TAXES AN_3

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Income Tax Disclosure [Abstract]
Loss from Continuing Operations Before Provision for Income Taxes	$ (49,548,705)	$ (60,651,820)	$ (103,314,604)	$ (196,997,174)
Income Tax Benefit (Expense)	$ 32,207,910	$ 13,836,022	$ (2,101,121)	$ 47,088,266
Effective Tax Rate	65.00%	23.00%	2.00%	24.00%

PROVISION FOR INCOME TAXES AN_4

PROVISION FOR INCOME TAXES AND DEFERRED INCOME TAXES (Details Narrative)	9 Months Ended
	Mar. 27, 2021USD ($)
Income Tax Disclosure [Abstract]
Net operating losses	$ 76,700,000
Unrealized net operating loss	$ 2,500,000
Operating loss expiration date	Dec. 31, 2038

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	9 Months Ended
	Mar. 27, 2021	Jul. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Legal claim damages		$ 2,200,000
Payments for Legal Disputes Settlements	$ 2,400,000
Seeking damages	11,000,000
Accrued damages	$ 584,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	9 Months Ended
	Mar. 27, 2021	Jul. 27, 2020
Restructuring support fees paid	$ 2,172,709
Fund LP II [Member]
Due from related party		$ 1,820,204
Due to related party		1,093,896
FundLP [Member]
Due from related party		1,289,513
Due to related party		1,986,697
Other [Member]
Due to other related party	$ 1,476,921
Due to related party		$ 1,476,221
Lynch [Member]
Stock option received	124,868
Bossidy [Member]
Stock option received	124,868

DISCONTINUED OPERATIONS (Detail

DISCONTINUED OPERATIONS (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Discontinued Operations and Disposal Groups [Abstract]
Revenue	$ 7,387,484	$ 5,865,570	$ 15,768,813	$ 18,856,242
Cost of goods sold	4,621,955	4,746,321	9,788,393	14,051,806
Gross Profit	2,765,529	1,119,249	5,980,420	4,804,436
Expenses:
General and Administrative	3,215,889	4,471,200	9,415,436	14,853,915
Sales and Marketing	21,756	2,986	52,857	45,991
Depreciation and Amortization	1,003,276	518,691	2,528,380	2,932,558
Gain on Disposal of Assets	(13,375,430)		(13,375,430)
Impairment Expense				46,702,659
Total Expenses	(9,134,509)	4,992,877	(1,378,757)	64,535,123
Operating Income (Loss) from Discontinued Operations	11,900,038	(3,873,628)	7,359,177	(59,730,687)
Other Expense (Income):
Interest Expense	2,629,476	1,985,129	7,549,165	4,066,905
Interest Income	(1,545)		(1,545)
Amortization of Debt Discount and Loan Origination Fees	2,197,946	323,916	5,834,043	3,444,098
Other (Income) Expense	(177,006)	(584)	(174,341)	77,494
Total Other Expense	4,648,871	2,308,461	13,207,322	7,588,497
Income (Loss) on Discontinued Operations Before Provision for Income Taxes	7,251,167	(6,182,089)	(5,848,145)	(67,319,184)
Provision for Income Tax Benefit (Expenses)	358,816	338,376	(175,284)	8,522,082
Income (Loss) on Discontinued Operations	$ 7,609,983	$ (5,843,713)	$ (6,023,429)	$ (58,797,102)

DISCONTINUED OPERATIONS (Deta_2

DISCONTINUED OPERATIONS (Details 1) - USD ($)	Mar. 27, 2021	Jun. 27, 2020
Carraying Amounts of the Assets Included in Assets Held For Sale
Cash and Cash Equivalents	$ 1,115,295	$ 1,198,390
Restricted Cash	5,280	8,844
Accounts Receivable	744,830	283,730
Prepaid Expenses	371,185	172,403
Inventory	6,252,896	6,985,120
Other Current Assets		64,600
Property and Equipment, Net	15,344,556	15,213,580
Operating Lease Right-of-Use Assets	24,428,302	26,349,789
Intangible Assets, Net	14,255,791	18,936,173
Goodwill	960,691	960,692
Other Assets	525,646	1,688,316
TOTAL ASSETS OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE	64,004,472	71,861,637
Carraying Amounts of the Liabilities Included in Liabilities Held For Sale
Accounts Payable and Accrued Liabilities	4,898,172	6,231,931
Income Taxes Payable	1,273,275	775,714
Total Accounts Payable and Accrued Liabilities	326,567	22,747
Current Portion of Operating Lease Liabilities	2,425,234	1,824,862
Operating Lease Liabilities, Net of Current Portion	25,540,209	25,417,774
Finance Lease Liabilities, Net of Current Portion	349,312
Deferred Tax Liabilities	9,710,451	14,663,497
TOTAL LIABILITIES OF THE DISPOSAL GROUP CLASSIFIED AS HELD FOR SALE	$ 44,523,220	$ 48,936,525

DISCONTINUED OPERATIONS (Deta_3

DISCONTINUED OPERATIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 27, 2021	Mar. 28, 2020	Mar. 27, 2021	Mar. 28, 2020
Discontinued Operations and Disposal Groups [Abstract]
Sales price			$ 25,150,000
Loss upon sale of membership interests			1,628,124
Interest expense and amortization of debt discounts and loan origination fees	$ 4,797,506	$ 2,308,388	$ 13,329,130	$ 7,507,064

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]	1 Months Ended
	Apr. 21, 2021$ / sharesshares
Warrant One [Member]
Exercise price | $ / shares	$ 0.26
Warrants Cancelled | shares	32,451,923
Warrant Two [Member]
Exercise price | $ / shares	$ 0.26
Warrants Cancelled | shares	6,490,385
Warrant Three [Member]
Exercise price | $ / shares	$ 0.20
Warrants Cancelled | shares	16,875,000
Warrant Four [Member]
Exercise price | $ / shares	$ 0.16
Warrants Cancelled | shares	41,967,832